0001527352 2026-01-01 2026-06-30 0001527352 2026-08-10 0001527352 2026-06-30 0001527352 2025-12-31 0001527352 2026-04-01 2026-06-30 0001527352 2025-04-01 2025-06-30 0001527352 2025-01-01 2025-06-30 0001527352 us-gaap:CommonStockMember 2024-12-31 0001527352 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0001527352 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001527352 us-gaap:RetainedEarningsMember 2024-12-31 0001527352 2024-12-31 0001527352 us-gaap:CommonStockMember 2025-03-31 0001527352 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-03-31 0001527352 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001527352 us-gaap:RetainedEarningsMember 2025-03-31 0001527352 2025-03-31 0001527352 us-gaap:CommonStockMember 2025-12-31 0001527352 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-12-31 0001527352 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0001527352 us-gaap:RetainedEarningsMember 2025-12-31 0001527352 us-gaap:CommonStockMember 2026-03-31 0001527352 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-03-31 0001527352 us-gaap:AdditionalPaidInCapitalMember 2026-03-31 0001527352 us-gaap:RetainedEarningsMember 2026-03-31 0001527352 2026-03-31 0001527352 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001527352 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-01-01 2025-03-31 0001527352 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001527352 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001527352 2025-01-01 2025-03-31 0001527352 us-gaap:CommonStockMember 2025-04-01 2025-06-30 0001527352 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-04-01 2025-06-30 0001527352 us-gaap:AdditionalPaidInCapitalMember 2025-04-01 2025-06-30 0001527352 us-gaap:RetainedEarningsMember 2025-04-01 2025-06-30 0001527352 us-gaap:CommonStockMember 2026-01-01 2026-03-31 0001527352 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-01-01 2026-03-31 0001527352 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-03-31 0001527352 us-gaap:RetainedEarningsMember 2026-01-01 2026-03-31 0001527352 2026-01-01 2026-03-31 0001527352 us-gaap:CommonStockMember 2026-04-01 2026-06-30 0001527352 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-04-01 2026-06-30 0001527352 us-gaap:AdditionalPaidInCapitalMember 2026-04-01 2026-06-30 0001527352 us-gaap:RetainedEarningsMember 2026-04-01 2026-06-30 0001527352 us-gaap:CommonStockMember 2025-06-30 0001527352 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-06-30 0001527352 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0001527352 us-gaap:RetainedEarningsMember 2025-06-30 0001527352 2025-06-30 0001527352 us-gaap:CommonStockMember 2026-06-30 0001527352 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-06-30 0001527352 us-gaap:AdditionalPaidInCapitalMember 2026-06-30 0001527352 us-gaap:RetainedEarningsMember 2026-06-30 0001527352 us-gaap:PatentsMember 2026-06-30 0001527352 us-gaap:TrademarksMember 2026-06-30 0001527352 us-gaap:PatentsMember 2025-12-31 0001527352 us-gaap:TrademarksMember 2025-12-31 0001527352 us-gaap:ShortTermInvestmentsMember 2026-06-30 0001527352 us-gaap:ShortTermInvestmentsMember 2026-01-01 2026-06-30 0001527352 us-gaap:ShortTermInvestmentsMember 2025-12-31 0001527352 us-gaap:ShortTermInvestmentsMember 2025-01-01 2025-12-31 0001527352 nxl:U.S.TreasuryNotesMember 2026-06-30 0001527352 us-gaap:FairValueInputsLevel1Member nxl:U.S.TreasuryNotesMember 2026-06-30 0001527352 us-gaap:FairValueInputsLevel2Member nxl:U.S.TreasuryNotesMember 2026-06-30 0001527352 us-gaap:FairValueInputsLevel3Member nxl:U.S.TreasuryNotesMember 2026-06-30 0001527352 nxl:MutualFundsMember 2026-06-30 0001527352 us-gaap:FairValueInputsLevel1Member nxl:MutualFundsMember 2026-06-30 0001527352 us-gaap:FairValueInputsLevel2Member nxl:MutualFundsMember 2026-06-30 0001527352 us-gaap:FairValueInputsLevel3Member nxl:MutualFundsMember 2026-06-30 0001527352 nxl:DeferredShareLiabilityMember 2026-06-30 0001527352 us-gaap:FairValueInputsLevel1Member nxl:DeferredShareLiabilityMember 2026-06-30 0001527352 us-gaap:FairValueInputsLevel3Member nxl:DeferredShareLiabilityMember 2026-06-30 0001527352 us-gaap:FairValueInputsLevel1Member 2026-06-30 0001527352 us-gaap:FairValueInputsLevel2Member 2026-06-30 0001527352 us-gaap:FairValueInputsLevel3Member 2026-06-30 0001527352 nxl:U.S.TreasuryNotesMember 2025-12-31 0001527352 us-gaap:FairValueInputsLevel1Member nxl:U.S.TreasuryNotesMember 2025-12-31 0001527352 us-gaap:FairValueInputsLevel2Member nxl:U.S.TreasuryNotesMember 2025-12-31 0001527352 us-gaap:FairValueInputsLevel3Member nxl:U.S.TreasuryNotesMember 2025-12-31 0001527352 nxl:MutualFundsMember 2025-12-31 0001527352 us-gaap:FairValueInputsLevel1Member nxl:MutualFundsMember 2025-12-31 0001527352 us-gaap:FairValueInputsLevel2Member nxl:MutualFundsMember 2025-12-31 0001527352 us-gaap:FairValueInputsLevel3Member nxl:MutualFundsMember 2025-12-31 0001527352 us-gaap:FairValueInputsLevel1Member 2025-12-31 0001527352 us-gaap:FairValueInputsLevel2Member 2025-12-31 0001527352 us-gaap:FairValueInputsLevel3Member 2025-12-31 0001527352 us-gaap:WarrantMember 2026-01-01 2026-06-30 0001527352 us-gaap:WarrantMember 2025-01-01 2025-06-30 0001527352 us-gaap:OptionMember 2026-01-01 2026-06-30 0001527352 us-gaap:OptionMember 2025-01-01 2025-06-30 0001527352 nxl:DeferredShareAwardsMember 2026-01-01 2026-06-30 0001527352 nxl:DeferredShareAwardsMember 2025-01-01 2025-06-30 0001527352 nxl:StockPurchaseAgreementMember 2026-01-01 2026-06-30 0001527352 nxl:LicensedTechnologyMember 2026-06-30 0001527352 nxl:USAsianConsultingGroupLLCMember nxl:AmendedAgreementMember 2018-05-01 2018-05-09 0001527352 nxl:USAsianConsultingGroupLLCMember nxl:AmendedAgreementMember 2026-01-01 2026-06-30 0001527352 nxl:USAsianConsultingGroupLLCMember 2026-06-30 0001527352 nxl:USAsianConsultingGroupLLCMember 2026-04-01 2026-06-30 0001527352 nxl:USAsianConsultingGroupLLCMember 2025-04-01 2025-06-30 0001527352 nxl:USAsianConsultingGroupLLCMember 2026-01-01 2026-06-30 0001527352 nxl:USAsianConsultingGroupLLCMember 2025-01-01 2025-06-30 0001527352 nxl:CollaborationAgreementMember 2026-01-01 2026-06-30 0001527352 nxl:CollaborationAgreementMember 2026-06-30 0001527352 nxl:ATMProgramMember 2026-01-01 2026-06-30 0001527352 nxl:PONMIncMember 2026-01-01 2026-06-30 0001527352 nxl:EmployeesAndBoardMembersMember 2026-01-01 2026-06-30 0001527352 nxl:OutsideConsultantMember 2026-01-01 2026-06-30 0001527352 nxl:EmployeesAndBoardMembersMember 2025-01-01 2025-06-30 0001527352 nxl:ATMProgramMember 2025-10-01 2025-10-15 0001527352 nxl:ATMProgramMember 2026-07-01 2026-08-14 0001527352 nxl:Plan2023Member 2026-03-15 0001527352 nxl:OutsideConsultantMember 2026-04-01 2026-06-30 0001527352 us-gaap:StockOptionMember 2025-12-31 0001527352 us-gaap:StockOptionMember 2025-01-01 2025-12-31 0001527352 us-gaap:StockOptionMember 2026-01-01 2026-06-30 0001527352 us-gaap:StockOptionMember 2026-06-30 0001527352 us-gaap:StockOptionMember nxl:Range01Member 2026-06-30 0001527352 us-gaap:StockOptionMember nxl:Range01Member 2026-01-01 2026-06-30 0001527352 us-gaap:StockOptionMember nxl:Range02Member 2026-06-30 0001527352 us-gaap:StockOptionMember nxl:Range02Member 2026-01-01 2026-06-30 0001527352 us-gaap:StockOptionMember nxl:Range03Member 2026-06-30 0001527352 us-gaap:StockOptionMember nxl:Range03Member 2026-01-01 2026-06-30 0001527352 us-gaap:StockOptionMember nxl:Range04Member 2026-06-30 0001527352 us-gaap:StockOptionMember nxl:Range04Member 2026-01-01 2026-06-30 0001527352 us-gaap:StockOptionMember nxl:Range05Member 2026-06-30 0001527352 us-gaap:StockOptionMember nxl:Range05Member 2026-01-01 2026-06-30 0001527352 us-gaap:StockOptionMember nxl:Range06Member 2026-06-30 0001527352 us-gaap:StockOptionMember nxl:Range06Member 2026-01-01 2026-06-30 0001527352 us-gaap:StockOptionMember nxl:Range07Member 2026-06-30 0001527352 us-gaap:StockOptionMember nxl:Range07Member 2026-01-01 2026-06-30 0001527352 us-gaap:StockOptionMember nxl:Range08Member 2026-06-30 0001527352 us-gaap:StockOptionMember nxl:Range08Member 2026-01-01 2026-06-30 0001527352 country:US 2026-04-01 2026-06-30 0001527352 country:US 2025-04-01 2025-06-30 0001527352 nxl:InternationalMember 2026-04-01 2026-06-30 0001527352 nxl:InternationalMember 2025-04-01 2025-06-30 0001527352 nxl:ClinicalTrialsMember 2026-04-01 2026-06-30 0001527352 nxl:ClinicalTrialsMember 2025-04-01 2025-06-30 0001527352 nxl:EDCBuildMember 2026-04-01 2026-06-30 0001527352 nxl:EDCBuildMember 2025-04-01 2025-06-30 0001527352 nxl:HALODesignMember 2026-04-01 2026-06-30 0001527352 nxl:HALODesignMember 2025-04-01 2025-06-30 0001527352 nxl:SYNCProjectMember 2026-04-01 2026-06-30 0001527352 nxl:SYNCProjectMember 2025-04-01 2025-06-30 0001527352 nxl:OtherResearchAndDevelopmentMember 2026-04-01 2026-06-30 0001527352 nxl:OtherResearchAndDevelopmentMember 2025-04-01 2025-06-30 0001527352 country:US 2026-01-01 2026-06-30 0001527352 country:US 2025-01-01 2025-06-30 0001527352 nxl:InternationalMember 2026-01-01 2026-06-30 0001527352 nxl:InternationalMember 2025-01-01 2025-06-30 0001527352 nxl:ClinicalTrialsMember 2026-01-01 2026-06-30 0001527352 nxl:ClinicalTrialsMember 2025-01-01 2025-06-30 0001527352 nxl:EDCBuildMember 2026-01-01 2026-06-30 0001527352 nxl:EDCBuildMember 2025-01-01 2025-06-30 0001527352 nxl:HALODesignMember 2026-01-01 2026-06-30 0001527352 nxl:HALODesignMember 2025-01-01 2025-06-30 0001527352 nxl:SYNCProjectMember 2026-01-01 2026-06-30 0001527352 nxl:SYNCProjectMember 2025-01-01 2025-06-30 0001527352 nxl:OtherResearchAndDevelopmentMember 2026-01-01 2026-06-30 0001527352 nxl:OtherResearchAndDevelopmentMember 2025-01-01 2025-06-30 0001527352 nxl:N2023EquityCompensationPlanMember 2026-08-01 2026-08-11 0001527352 2026-07-01 2026-07-28 iso4217:USD shares iso4217:USD shares false 2026 Q2 --12-31 0001527352

10-Q true 2026-06-30 false 001-41507 NEXALIN TECHNOLOGY, INC. DE 27-5566468 1776 Yorktown Street Suite 550 Houston TX 77056 832 260-0222 Common stock, par value $0.001 per share NXL NASDAQ Yes Yes Non-accelerated Filer true true false false 22036402

1004958

654783

3068429

7974 37812

52930

81571

233462

131473

570756

363014

1862106

4299270

9527

2683

42432

1099641

336049

3004179

4635319

239448

244579

858504

642754

386804

1484756

887333

1484756

887333

0.001

100000000

22003706

19186346

22003

19186

406

98700839

96595806

-97203419

-92867412

1519423

3747986

3004179

4635319

0 8275 0 11859

12161

70588

27111

111603

3264

22838

5081

36396

8897

47750

22030

75207

407444

178597

902740

546413

501717

370401

1000277

705759

782571

893836

1575368

1823056

564480

225774

910862

632062

2256212

1668608

4389247

3707290

-2247315

-1620858

-4367217

-3632083

-129

-4690

-163

-5793

8016

32438

29041

52557

2743

2006

5457

8145

39871

31210

63807

-2239170

-1580987

-4336007

-3568276

-2239170 -1580987 -4336007 -3568276 -1048

-2239170

-1580987

-4336007

-3569324

-406

513

-494

1343

-2239576

-1580474

-4336501

-3567981

-0.11

-0.10

-0.21

-0.25

21142920

15718149

20485567

14526149

13303523

13304

-513

88308478

-84645231

3676038

830

24406

636820

636844

-1988337

13327929

13328

317

88945298

-86633568

2325375

513

572100

4090000 4090 4642307 4646397

-1580987

17417929

17418

830

94159705

-88214555

5963398

19186346

19186

406

96595806

-92867412

3747986

478611

1395300 1395 755026 756421

-2096837

20581646

20581

494

97829443

-94964249

2886269

-494

408387

463044 463 137902 138365

959016

959

325107

326066

-2239170

22003706

22003

98700839

-97203419

1519423

-4336007

-3569324

886998

1208944

6844

27061

9912

29041

52557

864

-28641

49805

-3007

207742

-50086

101989

-1604

-5131

84631

215750

-30741

-3514616

-2343379

-8098254

-17701000

5001190

20103127

49276

42476

35215

35307 8841

2970005

-2446183

4646397

894786

4646397

350175

-143165

654783

574485

1004958

431320

724591 -11721 -406 1343

NOTE 1 — NATURE OF THE ORGANIZATION AND BUSINESS Corporate History Nexalin Technology, Inc. (the “Company” or “Nexalin”) was formed on November 17, 2021 as a Delaware corporation. We were originally formed as a Nevada corporation on October 19, 2010 as Nexalin Technology, Inc. (“Nexalin Nevada”). On December 1, 2021, we completed a corporate reorganization pursuant to which Nexalin Nevada merged with and into a newly incorporated Delaware company of the same name, Nexalin and, as a result, Nexalin succeeded Nexalin Nevada and each of the shareholders of Nexalin Nevada exchanged each of their shares in Nexalin Nevada for one twentieth (1/20th) of a common share of the newly formed Delaware corporation. Nexalin had nominal assets and liabilities and did not conduct any operations prior to the reorganization other than its incorporation. The Company’s principal offices are located at 1776 Yorktown Street, Suite 550, Houston, Texas 77056. Our shares and warrants began trading on September 16, 2022, and continues to be traded on the Nasdaq Capital Market tier of the Nasdaq Stock Market (“Nasdaq”), under the symbols “NXL” and “NXLIW”, respectively. In September 2025, the warrants expired, and were delisted. The common stock of the Company will continue to trade on the Nasdaq Capital Market under the symbol NXL. Throughout this Report, the terms “Nexalin,” “our,” “we,” “us,” and the “Company” refer to Nexalin Technology, Inc. Business Overview We are a medical device company engaged in the design and development of innovative neurostimulation products to uniquely and effectively help combat the ongoing global mental health epidemic. We developed an easy-to-administer medical device – referred to as “Generation 1” or “Gen-1” – that utilizes bioelectronic medical technology to treat anxiety, insomnia and depression without the need for drugs or psychotherapy. While the Gen-1 device had been cleared by the U.S. Food and Drug Administration (“FDA”) to treat depression, anxiety, and insomnia, because of the FDA’s December 2019 reclassification of cranial electrotherapy stimulation (CES) devices, the Gen-1 device was reclassified as a Class II device for the treatment of anxiety and insomnia, and as a Class III device for the treatment of depression. The waveform that comprises the basis of our “Generation 2” or “Gen-2”, “Gen-2 SYNC” or “SYNC” and new “Generation 3” or “Gen-3”, “Gen-3 HALO” or “HALO” headset devices have been in Q-submission process for review by the FDA. In October 2025, the FDA formally accepted our Q-Submission (“Q-Sub”) related to the Company’s Gen-2 Console (“SYNC”) system for the treatment of Alzheimer’s disease and dementia. The Company met with the FDA in November of 2025 and continues to develop a strategy and protocol. The acceptance of the Company’s request for interaction with the FDA with respect to its Gen-2 SYNC system represents a significant step toward Nexalin’s goal of achieving FDA authorization to begin U.S. clinical studies targeting Alzheimer’s and dementia — two of the most urgent unmet needs in healthcare. The Q-Submission process enables structured dialogue with and feedback from the FDA to discuss proposed clinical trial design, study endpoints, and regulatory pathway for evaluating the Gen-2 SYNC system as a potential non-invasive therapy for these debilitating neurodegenerative conditions, as well as for mild to moderate cognitive impairment (MCI) associated with Alzheimer’s disease. Determinations of the safety and efficacy of our devices in the United States are solely within the authority of the FDA. During the second quarter 2026, we initiated our FDA-cleared clinical trial evaluating the Gen-3 HALO device for the treatment of insomnia, and patient recruitment and enrollment are underway. We continue to work closely with the FDA as part of the De Novo regulatory pathway for the Gen-3 HALO device. Upon obtaining FDA marketing authorization through the De Novo process, we intend to further expand the development and commercialization of the Gen-3 HALO device in the United States and other territories, where we believe there is significant unmet need for the treatment of mental health conditions. During the second quarter of 2026, the Company expanded its technology portfolio through the acquisition of software and related intellectual property supporting its Nexalin NeuroCare™ digital health platform. Nexalin NeuroCare™ is designed to complement the Company’s neurostimulation technologies by providing software-enabled patient engagement, remote monitoring, physician workflow and clinical data management capabilities for clinical research and future commercial applications. All of our products are designed to be easy to administer, physically non-invasive and undetectable to the human body. They have been developed to provide relief to those afflicted with mental health issues, including anxiety, insomnia, depression and mild traumatic brain injury (mTBI). We utilize bioelectronic medical technology to treat these mental health issues. The determination of safety and efficacy of medical devices in the United States are subject to clearance by the FDA. Continued Nasdaq Listing Our shares of our common stock are listed on the Capital Market tier of the Nasdaq Stock Market, or Nasdaq, under the symbol “NXL.” Nasdaq has rules for continued listing, including, without limitation, minimum market capitalization, minimum stockholders’ equity and other requirements. In order to maintain that listing, we must satisfy minimum financial and other continued listing requirements and standards, including the Minimum Bid Price Rule (as discussed below) and those regarding director independence and independent committee requirements, minimum stockholders’ equity, and certain corporate governance requirements. There can be no assurances that we will be able to comply with the applicable listing standards. Minimum Bid Price Requirement We are required to maintain a minimum bid price of $1.00 per share. On January 21, 2026, the Company received a deficiency letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, based upon the closing bid price of the Company’s common stock, par value $0.001 per share, for the last 30 consecutive business days, the Company was not currently in compliance with the requirement to maintain a minimum bid price of $1.00 per share for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Requirement”). The Notice had no immediate effect on the continued listing of the Company’s common stock on The Nasdaq Capital Market. Under Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided a 180-calendar day compliance period, which expired on July 20, 2026, to regain compliance with the minimum bid price requirement. The Company did not regain compliance with the minimum bid price requirement during the initial compliance period and does not currently satisfy the requirements for an automatic additional 180-calendar day compliance period. Accordingly, on July 24, 2026, the Company received a Staff Delisting Determination from Nasdaq. The Company timely requested a hearing before the Nasdaq Hearings Panel. The hearing request is expected to stay any suspension of trading and delisting action pending the Panel’s decision. The Company continues to evaluate alternatives to regain compliance with the Nasdaq continued listing requirements, including, if determined appropriate by the Company’s Board of Directors (the “Board”), implementing the reverse stock split authorized by the Company’s stockholders at the 2026 Annual Meeting. There can be no assurance that the Hearings Panel will grant the Company’s request for continued listing or that the Company will ultimately regain compliance with the applicable Nasdaq continued listing requirements.

NOTE 2 — LIQUIDITY AND GOING CONCERN The accompanying unaudited condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As of June 30, 2026, the Company had an accumulated deficit of approximately $97,203,00097,203,419. For the six months ended June 30, 2026, the Company incurred a loss from operations of approximately $4,367,000 4,367,217 and used approximately $3,515,000 3,514,616 of cash in operating activities. Although the Company had working capital of approximately $377,000 as of June 30, 2026, its operating activities continue to consume the majority of its cash resources. The Company expects to continue to incur operating losses and negative cash flows as it advances its clinical development, regulatory and product development initiatives, including its ongoing clinical trial evaluating the Gen-3 HALO device for the treatment of insomnia, and pursues other strategic initiatives. Historically, the Company has funded its operations primarily through equity financings, including sales under its at-the-market offering program. The Company expects that additional capital will be required to fund its planned operations and strategic initiatives. Management’s plans include continuing to pursue additional equity financing, expanding international revenue opportunities, advancing its clinical and regulatory programs, and managing operating expenditures. The successful execution of these plans is dependent upon a number of factors, many of which are outside the Company’s control, including favorable capital market conditions and the Company’s ability to obtain additional financing on acceptable terms, or at all. After considering its plans, management concluded that the Company does not currently have sufficient cash and cash equivalents to fund its anticipated operating requirements for at least twelve months from the date these unaudited condensed consolidated financial statements are issued. Accordingly, management determined that its plans do not alleviate the substantial doubt about the Company’s ability to continue as a going concern. The accompanying unaudited condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

-97203419

-4367217

-3514616

377000

NOTE 3 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. Generally Accepted Accounting Principles in the United States (“GAAP”), for interim financial information and with the instruction for Quarterly Reports on Form 10-Q and Article 8 of Regulations S-X. Accordingly, the unaudited condensed consolidated financial statements do not include all the information and footnotes required by GAAP for complete annual financial statements. In the opinion of management, the accompanying unaudited condensed consolidated financial information includes all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the Company’s financial position and the operating results and cash flows. Operating results for the six months ended June 30, 2026 are not necessarily indicative of the results that may be expected for any other subsequent interim periods. These unaudited condensed consolidated financial statements and related notes should be read in conjunction with the Company’s audited consolidated financial statements for the year ended December 31, 2025 filed on March 25, 2026. The accompanying consolidated balance sheet as of December 31, 2025 has been derived from the audited financial statements included in our previously filed Annual Report on Form 10-K. Principles of Consolidation The unaudited condensed consolidated financial statements include the accounts of Nexalin Technology, Inc. and its wholly owned subsidiaries, Neuro-Health International, Inc. (“Neuro-Health”), PONM, Inc. (“PONM”) and Beijing Nexalin Neurotech Co., Ltd (“WOFE”). PONM has been included in the Company’s unaudited condensed consolidated financial statements from the date of its acquisition on May 14, 2026. Neuro-Health and WOFE had no operating activity during the periods presented. All intercompany accounts and transactions have been eliminated in consolidation. Use of Estimates The preparation of the unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, equity-based transactions, revenue and expenses and disclosure of contingent liabilities at the date of the unaudited condensed consolidated financial statements. The Company bases its estimates and assumptions on historical experience, known or expected trends and various other assumptions that it believes to be reasonable. As future events and their effects cannot be determined with precision, actual results could differ from these estimates, which may cause the Company’s future results to be affected. Asset Acquisitions The Company accounts for acquisitions that do not meet the definition of a business under Accounting Standards Codification (“ASC”) 805, Business Combinations, as asset acquisitions. The cost of an asset acquisition includes cash paid, the fair value of consideration transferred, and the estimated value of any deferred or other purchase consideration attributable to the acquired assets. When deferred purchase consideration is payable based on contractual terms and represents additional consideration for the acquired assets, the Company records a corresponding liability. Until such consideration is settled, the liability is remeasured to reflect changes in the estimated amount of consideration expected to be transferred. Corresponding adjustments are recorded as changes to the carrying amount of the related acquired asset and are not recognized in current-period earnings. The acquired asset is amortized over its estimated useful life, with the adjusted carrying amount serving as the basis for future amortization. Deferred Share Liability A deferred share liability represents the Company’s obligation to satisfy deferred purchase consideration through the future issuance of shares of its common stock. The deferred share liability is initially recognized at the estimated value of the unpaid purchase consideration and is subsequently remeasured at each reporting date until settlement. Changes in the carrying amount of the deferred share liability are recorded as adjustments to the carrying amount of the related acquired intangible asset in accordance with the Company’s accounting policy for asset acquisitions. Upon issuance of the Company’s common stock, the deferred share liability is reclassified to stockholders’ equity. Research and Development Advance payments made to contract research organizations and other clinical trial vendors are capitalized as prepaid assets and recognized as research and development expense as the underlying services are performed. Management periodically evaluates the status of services provided under each contract to determine the appropriate amount of expense to recognize during each reporting period. Patents and Trademarks Patents and trademarks are amortized over their useful lives and are reviewed for impairment when warranted by economic conditions. Amortization expense was approximately $8,000 and $14,000 and $5,000 and $10,000 for the three and six months ended June 30, 2026 and 2025, respectively. The following table summarizes the gross carrying amount, amortization and the net carrying value as of June 30, 2026 and December 31, 2025. <table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zzJNopWxFUi8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)"> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Schedule of patents</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td></tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Gross Carrying Amount</td> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Accumulated Amortization</td> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Net Carrying Value</td> <td style="padding-bottom: 0.5pt"> </td> </tr> <tr style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">June 30, 2026</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 9%; text-align: right"> </td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 9%; text-align: right"> </td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 9%; text-align: right"> </td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> </tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Patents</td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">318,200</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">(35,008</td> <td style="text-align: left; white-space: nowrap">)</td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">283,192</td> <td style="text-align: left; white-space: nowrap"> </td> </tr> <tr style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Trademarks</td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">136,291</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20260630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_pp0p" title="Accumulated Amortization">(19,982</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">116,309</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> </tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt">Total June 30, 2026</td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">454,491</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">(54,990</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt">)</td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">399,501</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> </tr> <tr style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> </tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">December 31, 2025</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> </tr> <tr style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Patents</td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">275,724</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">(27,008</td> <td style="text-align: left; white-space: nowrap">)</td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">248,716</td> <td style="text-align: left; white-space: nowrap"> </td> </tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Trademarks</td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">100,984</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_907_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20251231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_pp0p" title="Accumulated Amortization">(13,651</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">87,333</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> </tr> <tr style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt">Total December 31, 2025</td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">376,708</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">(40,659</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt">)</td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">336,049</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> </tr> </table> Fair Value Measurements As defined in ASC 820, Fair Value Measurements and Disclosures, fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (an exit price). In determining fair value, the Company uses valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs, and considers assumptions that market participants would use in pricing the asset or liability. ASC 820 establishes a fair value hierarchy that prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). This hierarchy applies to assets and liabilities measured at fair value on a recurring or nonrecurring basis. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.25in"> </td> <td style="width: 0.25in; text-align: left">●</td> <td style="text-align: justify">Level 1: Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that the Company can access at the measurement date.</td> </tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.25in"> </td> <td style="width: 0.25in; text-align: left">●</td> <td style="text-align: justify">Level 2: Inputs are observable, either directly or indirectly, other than quoted prices included in Level 1. These inputs may include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, or other observable market data.</td> </tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.25in"> </td> <td style="width: 0.25in; text-align: left">●</td> <td style="text-align: justify">Level 3: Inputs are unobservable and reflect the Company’s own assumptions about the assumptions market participants would use in pricing the asset or liability.</td> </tr> </table> The Company’s financial assets measured at fair value on a recurring basis consist of U.S. Treasury bills and mutual funds. The Company also measures its deferred share liability at fair value on a recurring basis until the underlying shares are issued. U.S. Treasury bills and mutual funds are classified within Level 1 of the fair value hierarchy based on quoted prices in active markets. The deferred share liability is classified within Level 1 of the fair value hierarchy based on the nature of the inputs used in its valuation. The fair value of the deferred share liability is determined using the quoted market price of the Company’s common stock, together with the applicable contractual terms governing the share issuance. There were no transfers between levels of the fair value hierarchy during the six months ended June 30, 2026. Fair Value of Financial Instruments The carrying amounts of cash, short-term investments, accounts receivable, inventory, prepaid expenses, accounts payable and accrued expenses, deferred share liability and other current liabilities approximate their fair values due to the short-term nature of these instruments, except for the deferred share liability, which is measured at fair value on a recurring basis. The following table summarizes the amortized cost, unrealized gain (loss) and the fair value as of June 30, 2026 and December 31, 2025. <table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_zD6h73NYLVCf" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1)"> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Schedule of unrealized loss on investments</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td></tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Amortized Cost</td> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Unrealized Loss</td> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Fair Value</td> <td style="padding-bottom: 0.5pt"> </td> </tr> <tr style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">June 30, 2026</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 9%; text-align: right"> </td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 9%; text-align: right"> </td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 9%; text-align: right"> </td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> </tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Short-term investments</td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td> <td style="border-bottom: Black 1pt solid; text-align: right">-</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td> <td style="border-bottom: Black 1pt solid; text-align: right">-</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td> <td style="border-bottom: Black 1pt solid; text-align: right">-</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> </tr> <tr style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> </tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">December 31, 2025</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> </tr> <tr style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Short-term investments</td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td> <td style="border-bottom: Black 1pt solid; text-align: right">3,068,023</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td> <td style="border-bottom: Black 1pt solid; text-align: right">406</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td> <td style="border-bottom: Black 1pt solid; text-align: right">3,068,429</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> </tr> </table> The following table provides the carrying value and fair value of the Company’s financial assets and liabilities measured at fair value as of June 30, 2026 and December 31, 2025. <table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisTextBlock_ztsoWK80L6af" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 2)"> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td id="xdx_8BB_zvdaXRKmZZy6" style="display: none; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Schedule of fair value, assets measured on recurring basis</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td></tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Carrying Value</td> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 1</td> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 2</td> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 3</td> <td style="padding-bottom: 0.5pt"> </td> </tr> <tr style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">June 30, 2026</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 9%; text-align: right"> </td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 9%; text-align: right"> </td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 9%; text-align: right"> </td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 9%; text-align: right"> </td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> </tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">U.S. Treasury Bill</td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">-</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_901_eus-gaap--AssetsFairValueDisclosure_c20260630__us-gaap--InvestmentTypeAxis__custom--U.S.TreasuryNotesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p" title="Financial assets">-</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_900_eus-gaap--AssetsFairValueDisclosure_c20260630__us-gaap--InvestmentTypeAxis__custom--U.S.TreasuryNotesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p" title="Financial assets">-</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_90E_eus-gaap--AssetsFairValueDisclosure_c20260630__us-gaap--InvestmentTypeAxis__custom--U.S.TreasuryNotesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p" title="Financial assets">-</td> <td style="text-align: left; white-space: nowrap"> </td> </tr> <tr style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Mutual Funds</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">-</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_902_eus-gaap--AssetsFairValueDisclosure_c20260630__us-gaap--InvestmentTypeAxis__custom--MutualFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p" title="Financial assets">-</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_903_eus-gaap--AssetsFairValueDisclosure_c20260630__us-gaap--InvestmentTypeAxis__custom--MutualFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p" title="Financial assets">-</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_904_eus-gaap--AssetsFairValueDisclosure_c20260630__us-gaap--InvestmentTypeAxis__custom--MutualFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p" title="Financial assets">-</td> <td style="text-align: left; white-space: nowrap"> </td> </tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Deferred share liability</td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">386,804</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">386,804</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_909_eus-gaap--AssetsFairValueDisclosure_c20260630__us-gaap--InvestmentTypeAxis__custom--DeferredShareLiabilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p" title="Financial assets">-</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90B_eus-gaap--AssetsFairValueDisclosure_c20260630__us-gaap--InvestmentTypeAxis__custom--DeferredShareLiabilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p" title="Financial assets">-</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> </tr> <tr style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt">Total June 30, 2026</td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">386,804</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">386,804</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">-</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">-</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> </tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> </tr> <tr style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">December 31, 2025</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> </tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">U.S. Treasury Bill</td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">2,700,824</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_904_eus-gaap--AssetsFairValueDisclosure_c20251231__us-gaap--InvestmentTypeAxis__custom--U.S.TreasuryNotesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p" title="Financial assets">2,700,824</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_903_eus-gaap--AssetsFairValueDisclosure_c20251231__us-gaap--InvestmentTypeAxis__custom--U.S.TreasuryNotesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p" title="Financial assets">-</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_902_eus-gaap--AssetsFairValueDisclosure_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--InvestmentTypeAxis__custom--U.S.TreasuryNotesMember_pp0p" title="Financial assets">-</td> <td style="text-align: left; white-space: nowrap"> </td> </tr> <tr style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Mutual Funds</td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">367,605</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90F_eus-gaap--AssetsFairValueDisclosure_c20251231__us-gaap--InvestmentTypeAxis__custom--MutualFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p" title="Financial assets">367,605</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_900_eus-gaap--AssetsFairValueDisclosure_c20251231__us-gaap--InvestmentTypeAxis__custom--MutualFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p" title="Financial assets">-</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_901_eus-gaap--AssetsFairValueDisclosure_c20251231__us-gaap--InvestmentTypeAxis__custom--MutualFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p" title="Financial assets">-</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> </tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt">Total December 31, 2025</td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">3,068,429</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">3,068,429</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">-</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">-</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> </tr> </table> As defined in ASC 820, Fair Value Measurements and Disclosures, fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). ASC 820 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). This framework applies to both initial and subsequent measurements. The deferred share liability is classified within Level 1 of the fair value hierarchy because its fair value is determined using the quoted market price of the Company’s common stock, which represents the significant input used in the valuation. Net Loss per Common Share Basic loss per common share excludes dilution and is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per common share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock, or otherwise resulted in the issuance of common stock that would share in the earnings of the Company. Potentially dilutive securities are excluded from the calculation of diluted net loss per share when their effect would be anti-dilutive. Accordingly, basic and diluted loss per share are the same for all periods presented. For all periods presented, certain potentially dilutive securities were excluded from the calculation of diluted loss per share because their effect would have been anti-dilutive. The following table summarizes the securities that would be excluded from the diluted per share calculation because the effect of including these potential shares was antidilutive due to the Company’s net loss position even though the exercise price could be less than the most recent fair value of the common shares: <table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z8gIP8Cjk3q3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 3)"> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td id="xdx_8B6_zB9OUlJYDtSf" style="display: none; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Schedule of anti-dilutive shares</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td></tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Three and Six Months Ended June 30,</td> <td style="padding-bottom: 0.5pt"> </td> </tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</td> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td> <td style="padding-bottom: 0.5pt"> </td> </tr> <tr style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Warrants</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 9%; text-align: right"><span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260101__20260630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pd" title="Total">-</td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 9%; text-align: right"><span id="xdx_902_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pd" title="Total">2,662,250</td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> </tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Options</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_90F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260101__20260630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--OptionMember_pd" title="Total">4,113,617</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--OptionMember_pd" title="Total">3,038,078</td> <td style="text-align: left; white-space: nowrap"> </td> </tr> <tr style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Deferred share awards</td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260101__20260630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--DeferredShareAwardsMember_pd" title="Total">510,989</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_903_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--DeferredShareAwardsMember_pd" title="Total">201,136</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> </tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt">Total</td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right">4,624,606</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right">5,901,464</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> </tr> </table> Stock-Based Compensation The Company applies the provisions of ASC 718, Compensation — Stock Compensation (the “guidance”), which requires the measurement and recognition of compensation expense for all stock-based awards granted to employees, including stock options, in the unaudited condensed consolidated statements of operations and comprehensive loss. For stock options issued to employees and members of the Board, the Company estimates the grant-date fair value of each option using the Black-Scholes option pricing model. This model requires management to make assumptions regarding the expected term of the option, the expected volatility of the Company’s common stock over the expected life of the option, risk-free interest rates, and expected dividend yields. For awards subject to service-based vesting conditions, including those with graded vesting schedules, the Company recognizes stock-based compensation expense on a straight-line basis over the requisite service period, which generally corresponds to the vesting term. Forfeitures are recognized as they occur, rather than being estimated at the grant date. Pursuant to ASU 2018-07, Compensation — Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting, the Company accounts for stock options and restricted shares issued to nonemployees in accordance with the guidance. Valuation methods and assumptions for nonemployee awards are consistent with those used for employee awards. Future Adoption of New Accounting Pronouncement In September 2025, the FASB issued ASU 2025-06, Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software. The guidance removes references to software development project stages so that capitalization is based on management authorization, commitment to funding, and probable completion for the intended use. The standard is effective for annual periods beginning after December 15, 2027, including interim periods, with prospective, modified, or retrospective transition methods allowed and early adoption permitted. The Company does not expect the adoption to have a material impact on its unaudited condensed consolidated financial statements. In November 2024, the FASB issued ASU 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40), which requires additional disaggregated disclosures of certain income statement expense categories. The standard is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the effect of adopting this guidance. All other newly issued but not yet effective accounting pronouncements are considered either not applicable or immaterial to the Company.

Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. Generally Accepted Accounting Principles in the United States (“GAAP”), for interim financial information and with the instruction for Quarterly Reports on Form 10-Q and Article 8 of Regulations S-X. Accordingly, the unaudited condensed consolidated financial statements do not include all the information and footnotes required by GAAP for complete annual financial statements. In the opinion of management, the accompanying unaudited condensed consolidated financial information includes all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the Company’s financial position and the operating results and cash flows. Operating results for the six months ended June 30, 2026 are not necessarily indicative of the results that may be expected for any other subsequent interim periods. These unaudited condensed consolidated financial statements and related notes should be read in conjunction with the Company’s audited consolidated financial statements for the year ended December 31, 2025 filed on March 25, 2026. The accompanying consolidated balance sheet as of December 31, 2025 has been derived from the audited financial statements included in our previously filed Annual Report on Form 10-K.

Principles of Consolidation The unaudited condensed consolidated financial statements include the accounts of Nexalin Technology, Inc. and its wholly owned subsidiaries, Neuro-Health International, Inc. (“Neuro-Health”), PONM, Inc. (“PONM”) and Beijing Nexalin Neurotech Co., Ltd (“WOFE”). PONM has been included in the Company’s unaudited condensed consolidated financial statements from the date of its acquisition on May 14, 2026. Neuro-Health and WOFE had no operating activity during the periods presented. All intercompany accounts and transactions have been eliminated in consolidation.

Use of Estimates The preparation of the unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, equity-based transactions, revenue and expenses and disclosure of contingent liabilities at the date of the unaudited condensed consolidated financial statements. The Company bases its estimates and assumptions on historical experience, known or expected trends and various other assumptions that it believes to be reasonable. As future events and their effects cannot be determined with precision, actual results could differ from these estimates, which may cause the Company’s future results to be affected.

Asset Acquisitions The Company accounts for acquisitions that do not meet the definition of a business under Accounting Standards Codification (“ASC”) 805, Business Combinations, as asset acquisitions. The cost of an asset acquisition includes cash paid, the fair value of consideration transferred, and the estimated value of any deferred or other purchase consideration attributable to the acquired assets. When deferred purchase consideration is payable based on contractual terms and represents additional consideration for the acquired assets, the Company records a corresponding liability. Until such consideration is settled, the liability is remeasured to reflect changes in the estimated amount of consideration expected to be transferred. Corresponding adjustments are recorded as changes to the carrying amount of the related acquired asset and are not recognized in current-period earnings. The acquired asset is amortized over its estimated useful life, with the adjusted carrying amount serving as the basis for future amortization.

Deferred Share Liability A deferred share liability represents the Company’s obligation to satisfy deferred purchase consideration through the future issuance of shares of its common stock. The deferred share liability is initially recognized at the estimated value of the unpaid purchase consideration and is subsequently remeasured at each reporting date until settlement. Changes in the carrying amount of the deferred share liability are recorded as adjustments to the carrying amount of the related acquired intangible asset in accordance with the Company’s accounting policy for asset acquisitions. Upon issuance of the Company’s common stock, the deferred share liability is reclassified to stockholders’ equity.

Research and Development Advance payments made to contract research organizations and other clinical trial vendors are capitalized as prepaid assets and recognized as research and development expense as the underlying services are performed. Management periodically evaluates the status of services provided under each contract to determine the appropriate amount of expense to recognize during each reporting period.

Patents and Trademarks Patents and trademarks are amortized over their useful lives and are reviewed for impairment when warranted by economic conditions. Amortization expense was approximately $8,000 and $14,000 and $5,000 and $10,000 for the three and six months ended June 30, 2026 and 2025, respectively. The following table summarizes the gross carrying amount, amortization and the net carrying value as of June 30, 2026 and December 31, 2025. <table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zzJNopWxFUi8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)"> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Schedule of patents</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td></tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Gross Carrying Amount</td> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Accumulated Amortization</td> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Net Carrying Value</td> <td style="padding-bottom: 0.5pt"> </td> </tr> <tr style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">June 30, 2026</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 9%; text-align: right"> </td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 9%; text-align: right"> </td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 9%; text-align: right"> </td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> </tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Patents</td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">318,200</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">(35,008</td> <td style="text-align: left; white-space: nowrap">)</td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">283,192</td> <td style="text-align: left; white-space: nowrap"> </td> </tr> <tr style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Trademarks</td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">136,291</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20260630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_pp0p" title="Accumulated Amortization">(19,982</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">116,309</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> </tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt">Total June 30, 2026</td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">454,491</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">(54,990</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt">)</td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">399,501</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> </tr> <tr style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> </tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">December 31, 2025</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> </tr> <tr style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Patents</td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">275,724</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">(27,008</td> <td style="text-align: left; white-space: nowrap">)</td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">248,716</td> <td style="text-align: left; white-space: nowrap"> </td> </tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Trademarks</td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">100,984</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_907_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20251231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_pp0p" title="Accumulated Amortization">(13,651</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">87,333</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> </tr> <tr style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt">Total December 31, 2025</td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">376,708</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">(40,659</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt">)</td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">336,049</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> </tr> </table>

8000

14000

5000

10000

<table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zzJNopWxFUi8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)"> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Schedule of patents</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td></tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Gross Carrying Amount</td> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Accumulated Amortization</td> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Net Carrying Value</td> <td style="padding-bottom: 0.5pt"> </td> </tr> <tr style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">June 30, 2026</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 9%; text-align: right"> </td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 9%; text-align: right"> </td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 9%; text-align: right"> </td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> </tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Patents</td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">318,200</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">(35,008</td> <td style="text-align: left; white-space: nowrap">)</td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">283,192</td> <td style="text-align: left; white-space: nowrap"> </td> </tr> <tr style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Trademarks</td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">136,291</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20260630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_pp0p" title="Accumulated Amortization">(19,982</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">116,309</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> </tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt">Total June 30, 2026</td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">454,491</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">(54,990</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt">)</td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">399,501</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> </tr> <tr style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> </tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">December 31, 2025</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> </tr> <tr style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Patents</td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">275,724</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">(27,008</td> <td style="text-align: left; white-space: nowrap">)</td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">248,716</td> <td style="text-align: left; white-space: nowrap"> </td> </tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Trademarks</td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">100,984</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_907_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20251231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_pp0p" title="Accumulated Amortization">(13,651</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">87,333</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> </tr> <tr style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt">Total December 31, 2025</td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">376,708</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">(40,659</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt">)</td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">336,049</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> </tr> </table>

318200

-35008

283192

136291

-19982

116309

454491

-54990

399501

275724

-27008

248716

100984

-13651

87333

376708

-40659

336049

Fair Value Measurements As defined in ASC 820, Fair Value Measurements and Disclosures, fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (an exit price). In determining fair value, the Company uses valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs, and considers assumptions that market participants would use in pricing the asset or liability. ASC 820 establishes a fair value hierarchy that prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). This hierarchy applies to assets and liabilities measured at fair value on a recurring or nonrecurring basis. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.25in"> </td> <td style="width: 0.25in; text-align: left">●</td> <td style="text-align: justify">Level 1: Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that the Company can access at the measurement date.</td> </tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.25in"> </td> <td style="width: 0.25in; text-align: left">●</td> <td style="text-align: justify">Level 2: Inputs are observable, either directly or indirectly, other than quoted prices included in Level 1. These inputs may include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, or other observable market data.</td> </tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.25in"> </td> <td style="width: 0.25in; text-align: left">●</td> <td style="text-align: justify">Level 3: Inputs are unobservable and reflect the Company’s own assumptions about the assumptions market participants would use in pricing the asset or liability.</td> </tr> </table> The Company’s financial assets measured at fair value on a recurring basis consist of U.S. Treasury bills and mutual funds. The Company also measures its deferred share liability at fair value on a recurring basis until the underlying shares are issued. U.S. Treasury bills and mutual funds are classified within Level 1 of the fair value hierarchy based on quoted prices in active markets. The deferred share liability is classified within Level 1 of the fair value hierarchy based on the nature of the inputs used in its valuation. The fair value of the deferred share liability is determined using the quoted market price of the Company’s common stock, together with the applicable contractual terms governing the share issuance. There were no transfers between levels of the fair value hierarchy during the six months ended June 30, 2026.

Fair Value of Financial Instruments The carrying amounts of cash, short-term investments, accounts receivable, inventory, prepaid expenses, accounts payable and accrued expenses, deferred share liability and other current liabilities approximate their fair values due to the short-term nature of these instruments, except for the deferred share liability, which is measured at fair value on a recurring basis. The following table summarizes the amortized cost, unrealized gain (loss) and the fair value as of June 30, 2026 and December 31, 2025. <table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_zD6h73NYLVCf" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1)"> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Schedule of unrealized loss on investments</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td></tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Amortized Cost</td> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Unrealized Loss</td> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Fair Value</td> <td style="padding-bottom: 0.5pt"> </td> </tr> <tr style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">June 30, 2026</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 9%; text-align: right"> </td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 9%; text-align: right"> </td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 9%; text-align: right"> </td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> </tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Short-term investments</td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td> <td style="border-bottom: Black 1pt solid; text-align: right">-</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td> <td style="border-bottom: Black 1pt solid; text-align: right">-</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td> <td style="border-bottom: Black 1pt solid; text-align: right">-</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> </tr> <tr style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> </tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">December 31, 2025</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> </tr> <tr style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Short-term investments</td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td> <td style="border-bottom: Black 1pt solid; text-align: right">3,068,023</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td> <td style="border-bottom: Black 1pt solid; text-align: right">406</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td> <td style="border-bottom: Black 1pt solid; text-align: right">3,068,429</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> </tr> </table> The following table provides the carrying value and fair value of the Company’s financial assets and liabilities measured at fair value as of June 30, 2026 and December 31, 2025. <table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisTextBlock_ztsoWK80L6af" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 2)"> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td id="xdx_8BB_zvdaXRKmZZy6" style="display: none; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Schedule of fair value, assets measured on recurring basis</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td></tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Carrying Value</td> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 1</td> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 2</td> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 3</td> <td style="padding-bottom: 0.5pt"> </td> </tr> <tr style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">June 30, 2026</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 9%; text-align: right"> </td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 9%; text-align: right"> </td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 9%; text-align: right"> </td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 9%; text-align: right"> </td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> </tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">U.S. Treasury Bill</td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">-</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_901_eus-gaap--AssetsFairValueDisclosure_c20260630__us-gaap--InvestmentTypeAxis__custom--U.S.TreasuryNotesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p" title="Financial assets">-</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_900_eus-gaap--AssetsFairValueDisclosure_c20260630__us-gaap--InvestmentTypeAxis__custom--U.S.TreasuryNotesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p" title="Financial assets">-</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_90E_eus-gaap--AssetsFairValueDisclosure_c20260630__us-gaap--InvestmentTypeAxis__custom--U.S.TreasuryNotesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p" title="Financial assets">-</td> <td style="text-align: left; white-space: nowrap"> </td> </tr> <tr style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Mutual Funds</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">-</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_902_eus-gaap--AssetsFairValueDisclosure_c20260630__us-gaap--InvestmentTypeAxis__custom--MutualFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p" title="Financial assets">-</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_903_eus-gaap--AssetsFairValueDisclosure_c20260630__us-gaap--InvestmentTypeAxis__custom--MutualFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p" title="Financial assets">-</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_904_eus-gaap--AssetsFairValueDisclosure_c20260630__us-gaap--InvestmentTypeAxis__custom--MutualFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p" title="Financial assets">-</td> <td style="text-align: left; white-space: nowrap"> </td> </tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Deferred share liability</td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">386,804</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">386,804</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_909_eus-gaap--AssetsFairValueDisclosure_c20260630__us-gaap--InvestmentTypeAxis__custom--DeferredShareLiabilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p" title="Financial assets">-</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90B_eus-gaap--AssetsFairValueDisclosure_c20260630__us-gaap--InvestmentTypeAxis__custom--DeferredShareLiabilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p" title="Financial assets">-</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> </tr> <tr style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt">Total June 30, 2026</td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">386,804</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">386,804</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">-</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">-</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> </tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> </tr> <tr style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">December 31, 2025</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> </tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">U.S. Treasury Bill</td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">2,700,824</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_904_eus-gaap--AssetsFairValueDisclosure_c20251231__us-gaap--InvestmentTypeAxis__custom--U.S.TreasuryNotesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p" title="Financial assets">2,700,824</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_903_eus-gaap--AssetsFairValueDisclosure_c20251231__us-gaap--InvestmentTypeAxis__custom--U.S.TreasuryNotesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p" title="Financial assets">-</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_902_eus-gaap--AssetsFairValueDisclosure_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--InvestmentTypeAxis__custom--U.S.TreasuryNotesMember_pp0p" title="Financial assets">-</td> <td style="text-align: left; white-space: nowrap"> </td> </tr> <tr style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Mutual Funds</td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">367,605</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90F_eus-gaap--AssetsFairValueDisclosure_c20251231__us-gaap--InvestmentTypeAxis__custom--MutualFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p" title="Financial assets">367,605</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_900_eus-gaap--AssetsFairValueDisclosure_c20251231__us-gaap--InvestmentTypeAxis__custom--MutualFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p" title="Financial assets">-</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_901_eus-gaap--AssetsFairValueDisclosure_c20251231__us-gaap--InvestmentTypeAxis__custom--MutualFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p" title="Financial assets">-</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> </tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt">Total December 31, 2025</td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">3,068,429</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">3,068,429</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">-</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">-</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> </tr> </table> As defined in ASC 820, Fair Value Measurements and Disclosures, fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). ASC 820 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). This framework applies to both initial and subsequent measurements. The deferred share liability is classified within Level 1 of the fair value hierarchy because its fair value is determined using the quoted market price of the Company’s common stock, which represents the significant input used in the valuation.

<table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_zD6h73NYLVCf" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1)"> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Schedule of unrealized loss on investments</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td></tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Amortized Cost</td> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Unrealized Loss</td> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Fair Value</td> <td style="padding-bottom: 0.5pt"> </td> </tr> <tr style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">June 30, 2026</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 9%; text-align: right"> </td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 9%; text-align: right"> </td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 9%; text-align: right"> </td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> </tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Short-term investments</td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td> <td style="border-bottom: Black 1pt solid; text-align: right">-</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td> <td style="border-bottom: Black 1pt solid; text-align: right">-</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td> <td style="border-bottom: Black 1pt solid; text-align: right">-</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> </tr> <tr style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> </tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">December 31, 2025</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> </tr> <tr style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Short-term investments</td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td> <td style="border-bottom: Black 1pt solid; text-align: right">3,068,023</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td> <td style="border-bottom: Black 1pt solid; text-align: right">406</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td> <td style="border-bottom: Black 1pt solid; text-align: right">3,068,429</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> </tr> </table>

3068023 406

3068429

<table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisTextBlock_ztsoWK80L6af" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 2)"> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td id="xdx_8BB_zvdaXRKmZZy6" style="display: none; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Schedule of fair value, assets measured on recurring basis</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td></tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Carrying Value</td> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 1</td> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 2</td> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 3</td> <td style="padding-bottom: 0.5pt"> </td> </tr> <tr style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">June 30, 2026</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 9%; text-align: right"> </td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 9%; text-align: right"> </td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 9%; text-align: right"> </td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 9%; text-align: right"> </td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> </tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">U.S. Treasury Bill</td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">-</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_901_eus-gaap--AssetsFairValueDisclosure_c20260630__us-gaap--InvestmentTypeAxis__custom--U.S.TreasuryNotesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p" title="Financial assets">-</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_900_eus-gaap--AssetsFairValueDisclosure_c20260630__us-gaap--InvestmentTypeAxis__custom--U.S.TreasuryNotesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p" title="Financial assets">-</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_90E_eus-gaap--AssetsFairValueDisclosure_c20260630__us-gaap--InvestmentTypeAxis__custom--U.S.TreasuryNotesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p" title="Financial assets">-</td> <td style="text-align: left; white-space: nowrap"> </td> </tr> <tr style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Mutual Funds</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">-</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_902_eus-gaap--AssetsFairValueDisclosure_c20260630__us-gaap--InvestmentTypeAxis__custom--MutualFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p" title="Financial assets">-</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_903_eus-gaap--AssetsFairValueDisclosure_c20260630__us-gaap--InvestmentTypeAxis__custom--MutualFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p" title="Financial assets">-</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_904_eus-gaap--AssetsFairValueDisclosure_c20260630__us-gaap--InvestmentTypeAxis__custom--MutualFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p" title="Financial assets">-</td> <td style="text-align: left; white-space: nowrap"> </td> </tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Deferred share liability</td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">386,804</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">386,804</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_909_eus-gaap--AssetsFairValueDisclosure_c20260630__us-gaap--InvestmentTypeAxis__custom--DeferredShareLiabilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p" title="Financial assets">-</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90B_eus-gaap--AssetsFairValueDisclosure_c20260630__us-gaap--InvestmentTypeAxis__custom--DeferredShareLiabilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p" title="Financial assets">-</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> </tr> <tr style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt">Total June 30, 2026</td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">386,804</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">386,804</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">-</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">-</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> </tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> </tr> <tr style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">December 31, 2025</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> </tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">U.S. Treasury Bill</td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">2,700,824</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_904_eus-gaap--AssetsFairValueDisclosure_c20251231__us-gaap--InvestmentTypeAxis__custom--U.S.TreasuryNotesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p" title="Financial assets">2,700,824</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_903_eus-gaap--AssetsFairValueDisclosure_c20251231__us-gaap--InvestmentTypeAxis__custom--U.S.TreasuryNotesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p" title="Financial assets">-</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_902_eus-gaap--AssetsFairValueDisclosure_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--InvestmentTypeAxis__custom--U.S.TreasuryNotesMember_pp0p" title="Financial assets">-</td> <td style="text-align: left; white-space: nowrap"> </td> </tr> <tr style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Mutual Funds</td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">367,605</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90F_eus-gaap--AssetsFairValueDisclosure_c20251231__us-gaap--InvestmentTypeAxis__custom--MutualFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p" title="Financial assets">367,605</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_900_eus-gaap--AssetsFairValueDisclosure_c20251231__us-gaap--InvestmentTypeAxis__custom--MutualFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p" title="Financial assets">-</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_901_eus-gaap--AssetsFairValueDisclosure_c20251231__us-gaap--InvestmentTypeAxis__custom--MutualFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p" title="Financial assets">-</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> </tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt">Total December 31, 2025</td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">3,068,429</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">3,068,429</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">-</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">-</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> </tr> </table>

386804

2700824

367605

3068429

Net Loss per Common Share Basic loss per common share excludes dilution and is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per common share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock, or otherwise resulted in the issuance of common stock that would share in the earnings of the Company. Potentially dilutive securities are excluded from the calculation of diluted net loss per share when their effect would be anti-dilutive. Accordingly, basic and diluted loss per share are the same for all periods presented. For all periods presented, certain potentially dilutive securities were excluded from the calculation of diluted loss per share because their effect would have been anti-dilutive. The following table summarizes the securities that would be excluded from the diluted per share calculation because the effect of including these potential shares was antidilutive due to the Company’s net loss position even though the exercise price could be less than the most recent fair value of the common shares: <table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z8gIP8Cjk3q3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 3)"> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td id="xdx_8B6_zB9OUlJYDtSf" style="display: none; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Schedule of anti-dilutive shares</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td></tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Three and Six Months Ended June 30,</td> <td style="padding-bottom: 0.5pt"> </td> </tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</td> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td> <td style="padding-bottom: 0.5pt"> </td> </tr> <tr style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Warrants</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 9%; text-align: right"><span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260101__20260630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pd" title="Total">-</td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 9%; text-align: right"><span id="xdx_902_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pd" title="Total">2,662,250</td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> </tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Options</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_90F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260101__20260630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--OptionMember_pd" title="Total">4,113,617</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--OptionMember_pd" title="Total">3,038,078</td> <td style="text-align: left; white-space: nowrap"> </td> </tr> <tr style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Deferred share awards</td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260101__20260630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--DeferredShareAwardsMember_pd" title="Total">510,989</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_903_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--DeferredShareAwardsMember_pd" title="Total">201,136</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> </tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt">Total</td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right">4,624,606</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right">5,901,464</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> </tr> </table>

<table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z8gIP8Cjk3q3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 3)"> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td id="xdx_8B6_zB9OUlJYDtSf" style="display: none; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Schedule of anti-dilutive shares</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td></tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Three and Six Months Ended June 30,</td> <td style="padding-bottom: 0.5pt"> </td> </tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</td> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td> <td style="padding-bottom: 0.5pt"> </td> </tr> <tr style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Warrants</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 9%; text-align: right"><span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260101__20260630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pd" title="Total">-</td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 9%; text-align: right"><span id="xdx_902_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pd" title="Total">2,662,250</td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> </tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Options</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_90F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260101__20260630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--OptionMember_pd" title="Total">4,113,617</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--OptionMember_pd" title="Total">3,038,078</td> <td style="text-align: left; white-space: nowrap"> </td> </tr> <tr style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Deferred share awards</td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260101__20260630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--DeferredShareAwardsMember_pd" title="Total">510,989</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_903_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--DeferredShareAwardsMember_pd" title="Total">201,136</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> </tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt">Total</td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right">4,624,606</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right">5,901,464</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> </tr> </table>

2662250

4113617

3038078

510989

201136

4624606

5901464

Stock-Based Compensation The Company applies the provisions of ASC 718, Compensation — Stock Compensation (the “guidance”), which requires the measurement and recognition of compensation expense for all stock-based awards granted to employees, including stock options, in the unaudited condensed consolidated statements of operations and comprehensive loss. For stock options issued to employees and members of the Board, the Company estimates the grant-date fair value of each option using the Black-Scholes option pricing model. This model requires management to make assumptions regarding the expected term of the option, the expected volatility of the Company’s common stock over the expected life of the option, risk-free interest rates, and expected dividend yields. For awards subject to service-based vesting conditions, including those with graded vesting schedules, the Company recognizes stock-based compensation expense on a straight-line basis over the requisite service period, which generally corresponds to the vesting term. Forfeitures are recognized as they occur, rather than being estimated at the grant date. Pursuant to ASU 2018-07, Compensation — Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting, the Company accounts for stock options and restricted shares issued to nonemployees in accordance with the guidance. Valuation methods and assumptions for nonemployee awards are consistent with those used for employee awards.

Future Adoption of New Accounting Pronouncement In September 2025, the FASB issued ASU 2025-06, Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software. The guidance removes references to software development project stages so that capitalization is based on management authorization, commitment to funding, and probable completion for the intended use. The standard is effective for annual periods beginning after December 15, 2027, including interim periods, with prospective, modified, or retrospective transition methods allowed and early adoption permitted. The Company does not expect the adoption to have a material impact on its unaudited condensed consolidated financial statements. In November 2024, the FASB issued ASU 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40), which requires additional disaggregated disclosures of certain income statement expense categories. The standard is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the effect of adopting this guidance. All other newly issued but not yet effective accounting pronouncements are considered either not applicable or immaterial to the Company.

NOTE 4 — ACQUISITION OF PONM, INC. On May 14, 2026, the Company completed the acquisition of 100% of the outstanding equity interests of PONM pursuant to a Stock Purchase Agreement with GreenLight Ventures, LLC (“GLV” and the agreement, the “Stock Purchase Agreement”). Immediately prior to the acquisition, PONM entered into a License Agreement with GLV (the “License Agreement”) pursuant to which PONM obtained an exclusive license to certain software and related intellectual property within specified fields of use. Concurrently with the acquisition, the Company entered into a Collaboration Agreement with GLV (“the “Collaboration Agreement”) under which GLV will provide ongoing software development, maintenance and related support services. Management believes the licensed software and related intellectual property acquired through the transaction represent the foundational technology supporting the continued development of the Company’s Nexalin NeuroCare™ platform. Prior to the acquisition, PONM had limited operations and substantially all of the value acquired by the Company related to the exclusive software license and related intellectual property obtained pursuant to the License Agreement with GLV. The Company determined that the acquisition did not meet the definition of a business under ASC 805, Business Combinations, and therefore accounted for the transaction as an asset acquisition. Substantially all of the value acquired relates to the licensed software and related intellectual property, which has been recorded as a finite-lived intangible asset and is being amortized over its estimated useful life. The aggregate purchase consideration is approximately $1.3 million and is payable through the issuance of shares of the Company’s common stock (“Consideration Shares”) in accordance with the issuance schedule contained in the Stock Purchase Agreement. The Consideration Shares are issuable in four tranches: 45% at closing; 20%, on the date that is 90 days after the closing date; 20%, on the date that is 180 days after the closing date; and 15%, on the date that is 270 days after the closing date. Closing of the first tranche under the Purchase Agreement occurred, and the Company issued the initial tranche of the Consideration Shares, or 959,016 shares of common stock, on May 14, 2026 (initial fair value of approximately $725,000). The unissued Consideration Shares are subject to specified protective provisions prior to issuance of the final tranche, including down-round protection for certain issuances below the applicable per share price, equitable adjustment for stock splits, reverse stock splits, recapitalizations, reclassifications and similar capital adjustments, and delisting protection, in each case, subject to a floor of $0.61 per share and a ceiling of $1.15 per share. The Purchase Agreement also provides for an acceleration of the issuance of all remaining unissued Consideration Shares upon a change of control of the Company. As a result, the number of shares ultimately issued may vary, while the aggregate purchase consideration remains subject to the terms of the Stock Purchase Agreement. At closing, the Company issued the initial tranche of common shares. The remaining consideration will be settled through future share issuances upon satisfaction of the applicable contractual issuance provisions. The Company recorded the remaining obligation as a liability, which is subsequently remeasured until each tranche of consideration is settled through the issuance of common stock. During the three months ended June 30, 2026, the Company adjusted the carrying amount of the acquired licensed technology for changes in the estimated amount of the remaining purchase consideration payable pursuant to the Stock Purchase Agreement (approximately $12,000). Such adjustments are capitalized as part of the cost of the acquired intangible asset and are not recognized in current-period earnings. The carrying amount of the related liability is adjusted concurrently until the remaining consideration is settled. Amortization expense related to the acquired intangible asset was approximately $13,000 for the three months ended June 30, 2026 and $13,000 for the six months ended June 30, 2026. <table cellpadding="0" cellspacing="0" id="xdx_88F_eus-gaap--ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock_zzLZS5MGiqI" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACQUISITION OF PONM, INC (Details)"> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td id="xdx_8B9_zv3EIv3peeH9" style="display: none; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Schedule of acquired intangible asset</td> <td style="padding-bottom: 0.5pt"> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td></tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Gross Carrying Amount</td> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Accumulated Amortization</td> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Net Carrying Value</td> <td style="padding-bottom: 0.5pt"> </td> </tr> <tr style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">June 30, 2026</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 9%; text-align: right"> </td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 9%; text-align: right"> </td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 9%; text-align: right"> </td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> </tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Licensed technology / intellectual property</td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td> <td style="border-bottom: Black 1pt solid; text-align: right">712,870</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td> <td style="border-bottom: Black 1pt solid; text-align: right">(12,730</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td> <td style="border-bottom: Black 1pt solid; text-align: right">700,140</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> </tr> <tr style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt">Total June 30, 2026</td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">712,870</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">(12,730</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt">)</td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">700,140</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> </tr> </table> The licensed technology and related intellectual property acquired in connection with the acquisition of PONM, Inc. is being amortized on a straight-line basis over its estimated useful life of 7 years. Future amortization is approximately $51,000 for the remaining of 2026, $102,000 for the years 2027 through 2032 and $37,000 for 2033. As a portion of the purchase consideration is payable through future issuances of the Company’s common stock, the Company recognized a deferred share liability representing the estimated value of the remaining purchase consideration to be settled in shares. The deferred share liability is presented as a separate line item on the accompanying unaudited condensed consolidated balance sheet (approximately $387,000 at June 30, 2026). In accordance with the Company’s accounting policy, the deferred share liability is remeasured until each tranche of consideration is settled through the issuance of common stock, with corresponding adjustments recorded to the carrying amount of the related intangible asset. The Company accounts for the deferred share liability in accordance with its accounting policies for asset acquisitions and deferred share liabilities described in Note 3 “Summary of Significant Accounting Policies”. Collaboration Agreement On May 14, 2026, the Company entered into a Collaboration Agreement with GLV to support the development, compliance and commercialization of the Company’s cranial electrotherapy stimulation technologies and related products using certain licensed software associated with GLV’s development of the Nexalin NeuroCare™ platform. Prior to the Company’s entry into the Purchase Agreement and the Collaboration Agreement, GLV and PONM entered into the License Agreement, under which PONM obtained an exclusive license to use certain GLV software within the PONM Field of Use. Under the Collaboration Agreement, GLV will provide development services under schedules of work and, upon request, infrastructure support services. Unless otherwise specified in a schedule of work, the Company will pay GLV $10,000 per month for such development services, with approved excess development services and approved infrastructure support services billed at rates set forth in the Collaboration Agreement. The Collaboration Agreement has an initial term of 24 months. The aggregate purchase consideration is approximately $1.3 million and is payable through the issuance of shares of the Company’s common stock (“Consideration Shares”) in accordance with the issuance schedule contained in the Stock Purchase Agreement. The Consideration Shares are issuable in four tranches: 45% at closing; 20%, on the date that is 90 days after the closing date; 20%, on the date that is 180 days after the closing date; and 15%, on the date that is 270 days after the closing date. Closing of the first tranche under the Purchase Agreement occurred, and the Company issued the initial tranche of the Consideration Shares, or 959,016 shares of common stock, on May 14, 2026 (initial fair value of approximately $725,000). The unissued Consideration Shares are subject to specified protective provisions prior to issuance of the final tranche, including down-round protection for certain issuances below the applicable per share price, equitable adjustment for stock splits, reverse stock splits, recapitalizations, reclassifications and similar capital adjustments, and delisting protection, in each case, subject to a floor of $0.61 per share and a ceiling of $1.15 per share. The Purchase Agreement also provides for an acceleration of the issuance of all remaining unissued Consideration Shares upon a change of control of the Company.

13000

<table cellpadding="0" cellspacing="0" id="xdx_88F_eus-gaap--ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock_zzLZS5MGiqI" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACQUISITION OF PONM, INC (Details)"> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td id="xdx_8B9_zv3EIv3peeH9" style="display: none; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Schedule of acquired intangible asset</td> <td style="padding-bottom: 0.5pt"> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td></tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Gross Carrying Amount</td> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Accumulated Amortization</td> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Net Carrying Value</td> <td style="padding-bottom: 0.5pt"> </td> </tr> <tr style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">June 30, 2026</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 9%; text-align: right"> </td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 9%; text-align: right"> </td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 9%; text-align: right"> </td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> </tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Licensed technology / intellectual property</td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td> <td style="border-bottom: Black 1pt solid; text-align: right">712,870</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td> <td style="border-bottom: Black 1pt solid; text-align: right">(12,730</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td> <td style="border-bottom: Black 1pt solid; text-align: right">700,140</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> </tr> <tr style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt">Total June 30, 2026</td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">712,870</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">(12,730</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt">)</td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">700,140</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> </tr> </table>

712870 -12730 700140 712870 -12730 700140

P7Y

51000

102000

37000

10000 NOTE 5 — PREPAID EXPENSES AND OTHER CURRENT ASSETS <table cellpadding="0" cellspacing="0" id="xdx_882_ecustom--ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_zqva3lvxLa3d" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)"> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td id="xdx_8B9_zyszeLwie432" style="display: none; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Schedule of prepaid expenses and other current assets</td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_493_20260630_zIQyvjsU0i56" style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_49B_20251231_zUnWTGE4iYo7" style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td></tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2026</td> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2025</td> <td style="padding-bottom: 0.5pt"> </td> </tr> <tr id="xdx_40F_ecustom--ContractResearchOrganizationCosts_iI_pp0d_maPEAOAzAlS_zKMW8eloiApb" style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Contract research organization costs</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">127,106</td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">-</td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> </tr> <tr id="xdx_40D_ecustom--InsuranceMedical_iI_pp0d_maPEAOAzAlS_zltrFmWK9Jj4" style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Insurance & medical</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">59,485</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">126,034</td> <td style="text-align: left; white-space: nowrap"> </td> </tr> <tr id="xdx_402_ecustom--Marketing_iI_pp0d_maPEAOAzAlS_zyqumbHdTITc" style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Marketing</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">115,000</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">15,000</td> <td style="text-align: left; white-space: nowrap"> </td> </tr> <tr id="xdx_40E_ecustom--ResearchAndDevelopment_iI_pp0d_maPEAOAzAlS_zQsPGYRsBRua" style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Research and development</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">36,753</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">33,333</td> <td style="text-align: left; white-space: nowrap"> </td> </tr> <tr id="xdx_407_eus-gaap--DeferredOfferingCosts_iI_pp0d_maPEAOAzAlS_zqdUdjhP7Jfe" style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Deferred offering costs</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">40,000</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">-</td> <td style="text-align: left; white-space: nowrap"> </td> </tr> <tr id="xdx_408_eus-gaap--MaterialsSuppliesAndOther_iI_pp0d_maPEAOAzAlS_zTpCl0w0e5nc" style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Materials and supplies</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">59,221</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">59,221</td> <td style="text-align: left; white-space: nowrap"> </td> </tr> <tr id="xdx_402_eus-gaap--ReceivablesNetCurrent_iI_pp0d_maPEAOAzAlS_zve6AM3NEoGc" style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Note receivable</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">81,000</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">81,000</td> <td style="text-align: left; white-space: nowrap"> </td> </tr> <tr id="xdx_40B_eus-gaap--OtherPrepaidExpenseCurrent_iI_pp0d_maPEAOAzAlS_z5n5Yq0hdvdi" style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Other</td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">52,191</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">48,426</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> </tr> <tr id="xdx_40A_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_pp0d_mtPEAOAzAlS_zd3hyJceMGwb" style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt">Total</td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">570,756</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">363,014</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> </tr> </table> The Company enters into agreements with contract research organizations (“CROs”) to conduct and manage clinical trials in support of its research and development activities. Advance payments made under these arrangements are recorded as prepaid clinical trial expenses and are recognized as research and development expense as the related services are performed, based on management’s assessment of the progress toward completion of the applicable contractual services. As of June 30, 2026, prepaid clinical trial expenses included approximately $127,000 of advance payments made under the Company’s agreement with its CRO in connection with the Company’s clinical trial evaluating the Gen-3 HALO device for the treatment of insomnia. <table cellpadding="0" cellspacing="0" id="xdx_882_ecustom--ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_zqva3lvxLa3d" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)"> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td id="xdx_8B9_zyszeLwie432" style="display: none; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Schedule of prepaid expenses and other current assets</td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_493_20260630_zIQyvjsU0i56" style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_49B_20251231_zUnWTGE4iYo7" style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td></tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2026</td> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2025</td> <td style="padding-bottom: 0.5pt"> </td> </tr> <tr id="xdx_40F_ecustom--ContractResearchOrganizationCosts_iI_pp0d_maPEAOAzAlS_zKMW8eloiApb" style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Contract research organization costs</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">127,106</td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">-</td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> </tr> <tr id="xdx_40D_ecustom--InsuranceMedical_iI_pp0d_maPEAOAzAlS_zltrFmWK9Jj4" style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Insurance & medical</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">59,485</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">126,034</td> <td style="text-align: left; white-space: nowrap"> </td> </tr> <tr id="xdx_402_ecustom--Marketing_iI_pp0d_maPEAOAzAlS_zyqumbHdTITc" style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Marketing</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">115,000</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">15,000</td> <td style="text-align: left; white-space: nowrap"> </td> </tr> <tr id="xdx_40E_ecustom--ResearchAndDevelopment_iI_pp0d_maPEAOAzAlS_zQsPGYRsBRua" style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Research and development</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">36,753</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">33,333</td> <td style="text-align: left; white-space: nowrap"> </td> </tr> <tr id="xdx_407_eus-gaap--DeferredOfferingCosts_iI_pp0d_maPEAOAzAlS_zqdUdjhP7Jfe" style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Deferred offering costs</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">40,000</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">-</td> <td style="text-align: left; white-space: nowrap"> </td> </tr> <tr id="xdx_408_eus-gaap--MaterialsSuppliesAndOther_iI_pp0d_maPEAOAzAlS_zTpCl0w0e5nc" style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Materials and supplies</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">59,221</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">59,221</td> <td style="text-align: left; white-space: nowrap"> </td> </tr> <tr id="xdx_402_eus-gaap--ReceivablesNetCurrent_iI_pp0d_maPEAOAzAlS_zve6AM3NEoGc" style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Note receivable</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">81,000</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">81,000</td> <td style="text-align: left; white-space: nowrap"> </td> </tr> <tr id="xdx_40B_eus-gaap--OtherPrepaidExpenseCurrent_iI_pp0d_maPEAOAzAlS_z5n5Yq0hdvdi" style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Other</td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">52,191</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">48,426</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> </tr> <tr id="xdx_40A_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_pp0d_mtPEAOAzAlS_zd3hyJceMGwb" style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt">Total</td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">570,756</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">363,014</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> </tr> </table> 127106 59485 126034 115000 15000 36753 33333

40000

59221

81000

52191

48426

570756

363014

127000

<p id="xdx_805_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_z0wjCZRmaNBc" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">NOTE 6 — ACCRUED EXPENSES Accrued expenses consist of the following amounts: <table cellpadding="0" cellspacing="0" id="xdx_88F_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zb9KhfjPAcFk" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACCRUED EXPENSES (Details)"> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td id="xdx_8B6_zUKVln7kUcxc" style="display: none; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Schedule of accrued expenses</td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_493_20260630_zlgCUO3tPAn2" style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_495_20251231_zTa75VhMiyFc" style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td></tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2026</td> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2025</td> <td style="padding-bottom: 0.5pt"> </td> </tr> <tr id="xdx_408_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pp0d_maAUCz0vM_zy1s9rBGihL1" style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Other</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">58,943</td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">87,581</td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> </tr> <tr id="xdx_40D_eus-gaap--AccruedBonusesCurrent_iI_pp0d_maAUCz0vM_z3FKxcjJdfIh" style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Bonuses</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">495,500</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">488,000</td> <td style="text-align: left; white-space: nowrap"> </td> </tr> <tr id="xdx_407_eus-gaap--AccruedProfessionalFeesCurrent_iI_pp0d_maAUCz0vM_zIhNtCQ1Dg96" style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Professional fees</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">122,500</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">-</td> <td style="text-align: left; white-space: nowrap"> </td> </tr> <tr id="xdx_406_eus-gaap--AccruedMarketingCostsCurrent_iI_pp0d_maAUCz0vM_z1rlqroZK8U5" style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Contract research organization costs</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">181,561</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">-</td> <td style="text-align: left; white-space: nowrap"> </td> </tr> <tr id="xdx_400_ecustom--AccruedResearchAndDevelopment_iI_pp0d_maAUCz0vM_zJHfsATYfzwd" style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Research and development</td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">-</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">67,173</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> </tr> <tr id="xdx_40E_eus-gaap--AccruedUtilitiesCurrent_iTI_pp0d_mtAUCz0vM_zgygVq3Zap4c" style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt">Total</td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">858,504</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">642,754</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> </tr> </table> Accrued bonuses include amounts earned by employees (including officers of the Company), which are expected to be paid in cash in the subsequent fiscal year. Certain amounts may be voluntarily deferred for cash management purposes. Accrued CRO expenses represent costs incurred under the Company’s CRO agreements for services performed as of June 30, 2026, but not yet invoiced or paid. Such costs are recognized as research and development expense based on management’s assessment of the progress toward completion of the applicable contractual services. As of June 30, 2026, accrued clinical trial expenses included approximately $182,000 related primarily to the Company’s agreement with its CRO in connection with the Company’s clinical trial evaluating the Gen-3 HALO device for the treatment of insomnia.

<table cellpadding="0" cellspacing="0" id="xdx_88F_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zb9KhfjPAcFk" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACCRUED EXPENSES (Details)"> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td id="xdx_8B6_zUKVln7kUcxc" style="display: none; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Schedule of accrued expenses</td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_493_20260630_zlgCUO3tPAn2" style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_495_20251231_zTa75VhMiyFc" style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td></tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2026</td> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2025</td> <td style="padding-bottom: 0.5pt"> </td> </tr> <tr id="xdx_408_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pp0d_maAUCz0vM_zy1s9rBGihL1" style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Other</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">58,943</td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">87,581</td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> </tr> <tr id="xdx_40D_eus-gaap--AccruedBonusesCurrent_iI_pp0d_maAUCz0vM_z3FKxcjJdfIh" style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Bonuses</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">495,500</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">488,000</td> <td style="text-align: left; white-space: nowrap"> </td> </tr> <tr id="xdx_407_eus-gaap--AccruedProfessionalFeesCurrent_iI_pp0d_maAUCz0vM_zIhNtCQ1Dg96" style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Professional fees</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">122,500</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">-</td> <td style="text-align: left; white-space: nowrap"> </td> </tr> <tr id="xdx_406_eus-gaap--AccruedMarketingCostsCurrent_iI_pp0d_maAUCz0vM_z1rlqroZK8U5" style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Contract research organization costs</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">181,561</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">-</td> <td style="text-align: left; white-space: nowrap"> </td> </tr> <tr id="xdx_400_ecustom--AccruedResearchAndDevelopment_iI_pp0d_maAUCz0vM_zJHfsATYfzwd" style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Research and development</td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">-</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">67,173</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> </tr> <tr id="xdx_40E_eus-gaap--AccruedUtilitiesCurrent_iTI_pp0d_mtAUCz0vM_zgygVq3Zap4c" style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt">Total</td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">858,504</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">642,754</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> </tr> </table>

58943

87581

495500

488000

122500

181561

67173

858504

642754

182000

NOTE 7 — RELATED PARTY TRANSACTIONS U.S. Asian Consulting Group, LLC On May 9, 2018, the Company entered into a five-year consulting agreement with U.S. Asian Consulting Group, LLC (“U.S. Asian”). The consulting agreement was extended for an additional period of eight years upon the closing of our initial public offering (expiring September 2030). The agreement was amended effective as of July 1, 2024 (“amended agreement”) to expand the services. The two members of U.S. Asian are shareholders in the Company including Marilyn Elson, who is the Company’s former controller, and Leonard Osser. Pursuant to the consulting agreement, U.S. Asian provides consulting services to the Company with regard to, among other things, corporate development, financing arrangements and international operations. The amended agreement calls for a monthly fee of $<span id="xdx_909_eus-gaap--DebtInstrumentPeriodicPayment_c20180501__20180509__srt--CounterpartyNameAxis__custom--USAsianConsultingGroupLLCMember__us-gaap--TypeOfArrangementAxis__custom--AmendedAgreementMember_pp0p" title="Monthly payment">16,667, a one-time stock grant (of <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesOther_c20260101__20260630__srt--CounterpartyNameAxis__custom--USAsianConsultingGroupLLCMember__us-gaap--TypeOfArrangementAxis__custom--AmendedAgreementMember_zzaNruy6UdQb" title="Shares issued">100,000 shares of common stock, with a grant date fair value of $<span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodValueOther_pp0d_c20260101__20260630__srt--CounterpartyNameAxis__custom--USAsianConsultingGroupLLCMember__us-gaap--TypeOfArrangementAxis__custom--AmendedAgreementMember_zXeX5l0ckWbk" title="Shares issued values">96,000) and a semi-annual share award equal to $<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueOther_c20180501__20180509__srt--CounterpartyNameAxis__custom--USAsianConsultingGroupLLCMember__us-gaap--TypeOfArrangementAxis__custom--AmendedAgreementMember_pp0p" title="Shares issued values">100,000 with the issuance and delivery of shares to take place following the termination/expirations of the consulting agreement. Deferred share awards as of June 30, 2026 are 510,989, per the terms of the agreement. The Company recorded approximately $20,000 and $44,000 for the three months ended June 30, 2026 and 2025, respectively, of stock compensation related to the semi-annual stock grants earned and approximately $50,000 for the three months ended June 30, 2026 and 2025, respectively, related to the monthly cash portion of the consulting agreement. The Company recorded approximately $70,000 and $94,000 for the six months ended June 30, 2026 and 2025, respectively, of stock compensation related to the semi-annual stock grants earned and approximately $100,000 for the six months ended June 30, 2026 and 2025, respectively, related to the monthly cash portion of the consulting agreement. Leases Our principal executive office is located at 1776 Yorktown, Suite 550, Houston, Texas 77056. Under ASC 842 “Leases”, we had a sub-lease (through IIcom Strategic Inc. controlled and owned by our Chief Executive Officer) totaling approximately 4,000 square feet of office space under an operating lease. Management and support staff are located at this location. The initial sub-lease expired in January of 2024. The Company entered into a new sublease for the same parties for additional space, which expired in February 2026, at which time the Company is paying month to month. Pursuant to the sublease, we paid the third-party landlord (not the sub landlord) all direct and indirect rent costs under the primary lease directly for the leased premises. No additional payments are made to the Chief Executive Officer or the entity controlled by him. Our lease costs paid to IIcom for each of the three and six months ended June 30, 2026 and 2025 were approximately $18,000 and $18,000 and $14,000 and $28,000, respectively. Subsequent to June 30, 2026, the Company entered into a Third Amendment to the office lease directly with the third-party landlord, replacing the related-party sublease arrangement and extending the lease term while expanding the leased premises. See Note 11, Subsequent Events, to the accompanying unaudited condensed consolidated financial statements for additional information. Collaboration Agreement The Company entered into a Collaboration Agreement with GLV in connection with the acquisition of PONM, Inc. Dr. David Owens, a member of the Company’s Board of Directors and our Chief Medical Officer, holds a minority ownership interest in GLV. During the three and six months ended June 30, 2026, the Company recognized approximately $38,000 of expense under the Collaboration Agreement, of which approximately $38,000 remained payable at June 30, 2026. The Collaboration Agreement was reviewed and approved in accordance with the Company’s related party transaction approval procedures.

16667

100000

96000

100000

510989

20000

44000

50000 50000

70000

94000

100000 100000

18000

14000

28000

38000 38000 38000

NOTE 8 — STOCKHOLDERS’ EQUITY Issuance of Common Stock During the six months ended June 30, 2026, the Company issued an aggregate of 2,817,360 shares of its common stock, as follows: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.25in"> </td> <td style="width: 0.25in; text-align: left">●</td> <td style="text-align: justify"><span id="xdx_904_ecustom--GrossProceedsFromIssuanceOfCommonStock_pp0d_c20260101__20260630__srt--ProductOrServiceAxis__custom--ATMProgramMember_z2dkUYoe0qma" title="Gross proceeds from issuance of common stock">1,858,344 shares of common stock were issued as part of our ATM program (as defined below), with net proceeds of approximately $895,000</td> </tr> <tr> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: left">●</td> <td style="text-align: justify">959,016 shares of its common stock in connection with the acquisition of 100% of the outstanding equity interests of PONM, Inc. Pursuant to the terms of the Stock Purchase Agreement, additional shares remain issuable as deferred purchase consideration and will be issued in accordance with the contractual issuance schedule. See Note 4 – Acquisition of PONM, Inc. for additional information.</td> </tr> </table> The Company recognized approximately $887,000 of stock-based compensation for the six months ended June 30, 2026, approximately $339,000 related to stock options noted below and approximately $548,000 for services rendered and paid in stock in lieu of cash by outside consultants, certain employees and Board Members. During the six months ended June 30, 2025, the Company issued an aggregate of 4,114,406 shares of its common stock, as follows: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.25in"> </td> <td style="width: 0.25in; text-align: left">●</td> <td style="text-align: justify">24,406 shares of common stock were issued for services in lieu of cash to an outside consultant.</td> </tr> <tr> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: left">●</td> <td style="text-align: justify">4,090,000 shares of common stock were issued as part of an equity offering, with net proceeds of approximately $4,646,000.</td> </tr> </table> The Company recognized approximately $1,209,000 of stock-based compensation for the six months ended June 30, 2025, approximately $471,000 related to stock options noted below and approximately $738,000 for services rendered and paid in stock in lieu of cash rendered by outside consultants, certain employees and Board Members. “At-the-Market” Offering On October 15, 2025, we entered into an Amendment No. 2 (the “Second Amendment”) to that certain equity distribution agreement, dated April 29, 2025 (the “Original Agreement”) as amended by that certain Amendment No. 1 to the Original Agreement, dated May 5, 2025, (the “First Amendment” and, together with the Original Agreement and the Second Amendment, the “Equity Distribution Agreement”) with Maxim Group LLC (“Maxim”), under which we currently have the ability to issue and sell shares of our common stock, from time to time, through Maxim, up to an aggregate offering price of approximately $4,273,000 (the “ATM program”). During the six months ended June 30, 2026 we sold 1,858,344 shares of our common stock under the ATM program for net proceeds of approximately $895,000. As of June 30, 2026 in total we have sold 2,549,751 shares of our common stock under the ATM program for gross proceeds of approximately $1,619,000. Subsequent to June 30, 2026 we have sold <span id="xdx_90C_ecustom--GrossProceedsFromIssuanceOfCommonStock_pp0d_c20260701__20260814__srt--ProductOrServiceAxis__custom--ATMProgramMember_zv9hJee4b5B1" title="Gross proceeds from issuance of common stock">32,696 shares of our common stock under the ATM program for gross proceeds of approximately $15,000. Options The Company’s 2023 Equity Incentive Plan (the “2023 Plan”) was approved by our stockholders on November 10, 2023. The 2023 Plan originally provided that the maximum number of shares of common stock available for the grant of awards under the 2023 Plan shall be 1,500,000, subject to adjustment for stock dividends, stock splits or similar events. The 2023 Plan is administered by the Compensation Committee of the Board, which may in turn delegate administrative authority to one or more of our executive officers. Under the terms of the 2023 Plan, the Compensation Committee may grant equity awards, including nonqualified stock options and restricted stock to employees, officers, directors, consultants, agents, advisors and independent contractors. The 2023 Plan has been amended, most recently as of July 15, 2025, to increase the number of shares under the 2023 Plan to <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c20260315__us-gaap--PlanNameAxis__custom--Plan2023Member_pd" title="Number of shares available for grant">9,000,000. Under the terms of the 2023 Plan, the Compensation Committee may grant equity awards, including nonqualified stock options and restricted stock to employees, officers, directors, consultants, agents, advisors and independent contractors. See Note 11 “Subsequent Events”. The amount expensed during the three and six months ended June 30, 2026 and 2025 in the unaudited condensed consolidated statements of operations and comprehensive loss related to stock options issued under the 2023 Plan was approximately $170,000 and $339,000 and $236,000 and $471,000, respectively. On December 19, 2025, the Board and the Compensation Committee approved the grant of stock options to certain employees and Board members, subject to shareholder approval. As of June 30, 2026, shareholder approval had not been obtained, and therefore no grant date had occurred, and no compensation expense has been recognized. See Note 11 “Subsequent Events”. The table below does not include 2,400,000 shares underlying stock options that are contingent on the above shareholder approval. The following table presents a summary of stock option award activity during the six months ended June 30, 2026: <table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zEadXAaMIQD8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (Details)"> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td id="xdx_8BB_zHoJ8mnEZZl1" style="display: none; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Schedule of stock option award activity</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td></tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of Options</td> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Exercise Price</td> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Remaining Life In Years</td> <td style="padding-bottom: 0.5pt"> </td> </tr> <tr style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Outstanding December 31, 2025</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 9%; text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zRcOdPB67yt6" title="Number of options outstanding, beginning balance">4,113,617</td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zGwXycG63Ech" title="Weighted average exercise price, options outstanding beginning balance">1.12</td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 9%; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zMpnm28Ph5p9" title="Weighted Average Remaining Life In years">5.80</td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> </tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Issued</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Number of options issued">-</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Weighted average exercise price, options issued">-</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">-</td> <td style="text-align: left; white-space: nowrap"> </td> </tr> <tr style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Exercised</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">-</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Weighted average exercise price, options exercised">-</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">-</td> <td style="text-align: left; white-space: nowrap"> </td> </tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Expired or cancelled</td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Number of options expired or cancelled">-</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Weighted average exercise price, options expired or cancelled">-</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">-</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> </tr> <tr style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt">Outstanding June 30, 2026</td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zTLEdNwNHN0h" title="Number of options outstanding, ending balance">4,113,617</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zqKHtuKGl3de" title="Weighted average exercise price, options outstanding ending balance">1.12</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zEPMmlgKpS8k" title="Weighted Average Remaining Life In years">5.31</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> </tr> </table> The following table provides additional information about stock options that are outstanding and exercisable as of June 30, 2026: <table cellpadding="0" cellspacing="0" id="xdx_897_ecustom--ScheduleOfAdditionalIinformationTableTextBlock_zbmhUgrB5M39" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (Details 1)"> <tr style="vertical-align: bottom"> <td id="xdx_8B3_zQV23P999Y66" style="display: none">Schedule of additional information about stock options</td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Exercise Price</td> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Outstanding Number of Options</td> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Remaining Life In Years</td> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Exercisable Number of Options</td> <td style="padding-bottom: 0.5pt"> </td> </tr> <tr style="vertical-align: bottom"> <td style="background-color: #CCEEFF; text-align: justify; width: 1%">$</td> <td style="background-color: #CCEEFF; text-align: right; width: 23%"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range01Member__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Exercise Price">0.89</td> <td style="background-color: #CCEEFF; width: 1%"> </td> <td style="background-color: #CCEEFF; width: 1%"> </td> <td style="background-color: #CCEEFF; width: 1%"> </td> <td style="background-color: #CCEEFF; text-align: right; width: 22%"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range01Member__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Outstanding Number of Options">2,181,208</td> <td style="background-color: #CCEEFF; width: 1%"> </td> <td style="background-color: #CCEEFF; width: 1%"> </td> <td style="background-color: #CCEEFF; text-align: justify; width: 1%">$</td> <td style="background-color: #CCEEFF; text-align: right; width: 22%"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range01Member__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z2OUh8WwnwVe" title="Weighted Average Remaining Life In Years">7.01</td> <td style="background-color: #CCEEFF; width: 1%"> </td> <td style="background-color: #CCEEFF; width: 1%"> </td> <td style="background-color: #CCEEFF; width: 1%"> </td> <td style="background-color: #CCEEFF; text-align: right; width: 22%"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range01Member__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Excercisable Number of Options">2,181,208</td> <td style="background-color: #CCEEFF; width: 1%"> </td> </tr> <tr style="vertical-align: bottom"> <td> </td> <td style="text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range02Member__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Exercise Price">0.94</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range02Member__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Outstanding Number of Options">581,250</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range02Member__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zAtY3dtX2RDe" title="Weighted Average Remaining Life In Years">2.45</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range02Member__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Excercisable Number of Options">581,250</td> <td> </td> </tr> <tr style="vertical-align: bottom"> <td style="background-color: #CCEEFF"> </td> <td style="background-color: #CCEEFF; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range03Member__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Exercise Price">0.66</td> <td style="background-color: #CCEEFF"> </td> <td style="background-color: #CCEEFF"> </td> <td style="background-color: #CCEEFF"> </td> <td style="background-color: #CCEEFF; text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range03Member__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Outstanding Number of Options">90,620</td> <td style="background-color: #CCEEFF"> </td> <td style="background-color: #CCEEFF"> </td> <td style="background-color: #CCEEFF"> </td> <td style="background-color: #CCEEFF; text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range03Member__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zUuOZbBs2Lye" title="Weighted Average Remaining Life In Years">3.24</td> <td style="background-color: #CCEEFF"> </td> <td style="background-color: #CCEEFF"> </td> <td style="background-color: #CCEEFF"> </td> <td style="background-color: #CCEEFF; text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range03Member__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Excercisable Number of Options">30,207</td> <td style="background-color: #CCEEFF"> </td> </tr> <tr style="vertical-align: bottom"> <td> </td> <td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range04Member__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Exercise Price">2.95</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range04Member__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Outstanding Number of Options">185,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range04Member__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zJSjAtyf5ljf" title="Weighted Average Remaining Life In Years">3.50</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range04Member__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Excercisable Number of Options">155,000</td> <td> </td> </tr> <tr style="vertical-align: bottom"> <td style="background-color: #CCEEFF"> </td> <td style="background-color: #CCEEFF; text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range05Member__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Exercise Price">3.25</td> <td style="background-color: #CCEEFF"> </td> <td style="background-color: #CCEEFF"> </td> <td style="background-color: #CCEEFF"> </td> <td style="background-color: #CCEEFF; text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range05Member__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Outstanding Number of Options">130,000</td> <td style="background-color: #CCEEFF"> </td> <td style="background-color: #CCEEFF"> </td> <td style="background-color: #CCEEFF"> </td> <td style="background-color: #CCEEFF; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range05Member__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zdXnYo8mA9e1" title="Weighted Average Remaining Life In Years">2.05</td> <td style="background-color: #CCEEFF"> </td> <td style="background-color: #CCEEFF"> </td> <td style="background-color: #CCEEFF"> </td> <td style="background-color: #CCEEFF; text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range05Member__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Excercisable Number of Options">130,000</td> <td style="background-color: #CCEEFF"> </td> </tr> <tr style="vertical-align: bottom"> <td> </td> <td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range06Member__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Exercise Price">1.15</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range06Member__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Outstanding Number of Options">430,435</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range06Member__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zcGQLCqmbhbh" title="Weighted Average Remaining Life In Years">4.06</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range06Member__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Excercisable Number of Options">245,218</td> <td> </td> </tr> <tr style="vertical-align: bottom"> <td style="background-color: #CCEEFF"> </td> <td style="background-color: #CCEEFF; text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range07Member__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Exercise Price">0.96</td> <td style="background-color: #CCEEFF"> </td> <td style="background-color: #CCEEFF"> </td> <td style="background-color: #CCEEFF"> </td> <td style="background-color: #CCEEFF; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range07Member__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Outstanding Number of Options">315,104</td> <td style="background-color: #CCEEFF"> </td> <td style="background-color: #CCEEFF"> </td> <td style="background-color: #CCEEFF"> </td> <td style="background-color: #CCEEFF; text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range07Member__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zrX0OFWeuax3" title="Weighted Average Remaining Life In Years">4.17</td> <td style="background-color: #CCEEFF"> </td> <td style="background-color: #CCEEFF"> </td> <td style="background-color: #CCEEFF"> </td> <td style="background-color: #CCEEFF; text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range07Member__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Excercisable Number of Options">315,104</td> <td style="background-color: #CCEEFF"> </td> </tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 0.5pt"> </td> <td style="text-align: right; padding-bottom: 0.5pt"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range08Member__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Exercise Price">1.50</td> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range08Member__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Outstanding Number of Options">200,000</td> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range08Member__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zUuYMvALLyda" title="Weighted Average Remaining Life In Years">4.28</td> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range08Member__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Excercisable Number of Options">200,000</td> <td style="padding-bottom: 0.5pt"> </td> </tr> <tr style="vertical-align: bottom"> <td style="background-color: #CCEEFF; padding-bottom: 1.25pt"> </td> <td style="background-color: #CCEEFF; padding-bottom: 1.25pt"> </td> <td style="background-color: #CCEEFF; padding-bottom: 1.25pt"> </td> <td style="background-color: #CCEEFF; padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; background-color: #CCEEFF"> </td> <td style="border-bottom: Black 2.5pt double; background-color: #CCEEFF; text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Outstanding Number of Options">4,113,617</td> <td style="background-color: #CCEEFF; padding-bottom: 1.25pt"> </td> <td style="background-color: #CCEEFF; padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; background-color: #CCEEFF; text-align: justify">$</td> <td style="border-bottom: Black 2.5pt double; background-color: #CCEEFF; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zBycLw1CWnR" title="Weighted Average Remaining Life In Years">5.31</td> <td style="background-color: #CCEEFF; padding-bottom: 1.25pt"> </td> <td style="background-color: #CCEEFF; padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; background-color: #CCEEFF"> </td> <td style="border-bottom: Black 2.5pt double; background-color: #CCEEFF; text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Excercisable Number of Options">3,837,986</td> <td style="background-color: #CCEEFF; padding-bottom: 1.25pt"> </td> </tr> </table>

2817360

1858344

895000

959016

887000

339000 548000

4114406

24406

4090000

4646000

1209000

471000 738000 4273000 1858344

895000

2549751 1619000 32696 15000

9000000

170000

339000

236000

471000

<table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zEadXAaMIQD8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (Details)"> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td id="xdx_8BB_zHoJ8mnEZZl1" style="display: none; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Schedule of stock option award activity</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td></tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of Options</td> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Exercise Price</td> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Remaining Life In Years</td> <td style="padding-bottom: 0.5pt"> </td> </tr> <tr style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Outstanding December 31, 2025</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 9%; text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zRcOdPB67yt6" title="Number of options outstanding, beginning balance">4,113,617</td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zGwXycG63Ech" title="Weighted average exercise price, options outstanding beginning balance">1.12</td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 9%; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zMpnm28Ph5p9" title="Weighted Average Remaining Life In years">5.80</td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> </tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Issued</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Number of options issued">-</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Weighted average exercise price, options issued">-</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">-</td> <td style="text-align: left; white-space: nowrap"> </td> </tr> <tr style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Exercised</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">-</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Weighted average exercise price, options exercised">-</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">-</td> <td style="text-align: left; white-space: nowrap"> </td> </tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Expired or cancelled</td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Number of options expired or cancelled">-</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Weighted average exercise price, options expired or cancelled">-</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">-</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> </tr> <tr style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt">Outstanding June 30, 2026</td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zTLEdNwNHN0h" title="Number of options outstanding, ending balance">4,113,617</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zqKHtuKGl3de" title="Weighted average exercise price, options outstanding ending balance">1.12</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zEPMmlgKpS8k" title="Weighted Average Remaining Life In years">5.31</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> </tr> </table> The following table provides additional information about stock options that are outstanding and exercisable as of June 30, 2026: <table cellpadding="0" cellspacing="0" id="xdx_897_ecustom--ScheduleOfAdditionalIinformationTableTextBlock_zbmhUgrB5M39" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (Details 1)"> <tr style="vertical-align: bottom"> <td id="xdx_8B3_zQV23P999Y66" style="display: none">Schedule of additional information about stock options</td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Exercise Price</td> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Outstanding Number of Options</td> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Remaining Life In Years</td> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Exercisable Number of Options</td> <td style="padding-bottom: 0.5pt"> </td> </tr> <tr style="vertical-align: bottom"> <td style="background-color: #CCEEFF; text-align: justify; width: 1%">$</td> <td style="background-color: #CCEEFF; text-align: right; width: 23%"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range01Member__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Exercise Price">0.89</td> <td style="background-color: #CCEEFF; width: 1%"> </td> <td style="background-color: #CCEEFF; width: 1%"> </td> <td style="background-color: #CCEEFF; width: 1%"> </td> <td style="background-color: #CCEEFF; text-align: right; width: 22%"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range01Member__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Outstanding Number of Options">2,181,208</td> <td style="background-color: #CCEEFF; width: 1%"> </td> <td style="background-color: #CCEEFF; width: 1%"> </td> <td style="background-color: #CCEEFF; text-align: justify; width: 1%">$</td> <td style="background-color: #CCEEFF; text-align: right; width: 22%"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range01Member__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z2OUh8WwnwVe" title="Weighted Average Remaining Life In Years">7.01</td> <td style="background-color: #CCEEFF; width: 1%"> </td> <td style="background-color: #CCEEFF; width: 1%"> </td> <td style="background-color: #CCEEFF; width: 1%"> </td> <td style="background-color: #CCEEFF; text-align: right; width: 22%"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range01Member__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Excercisable Number of Options">2,181,208</td> <td style="background-color: #CCEEFF; width: 1%"> </td> </tr> <tr style="vertical-align: bottom"> <td> </td> <td style="text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range02Member__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Exercise Price">0.94</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range02Member__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Outstanding Number of Options">581,250</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range02Member__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zAtY3dtX2RDe" title="Weighted Average Remaining Life In Years">2.45</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range02Member__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Excercisable Number of Options">581,250</td> <td> </td> </tr> <tr style="vertical-align: bottom"> <td style="background-color: #CCEEFF"> </td> <td style="background-color: #CCEEFF; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range03Member__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Exercise Price">0.66</td> <td style="background-color: #CCEEFF"> </td> <td style="background-color: #CCEEFF"> </td> <td style="background-color: #CCEEFF"> </td> <td style="background-color: #CCEEFF; text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range03Member__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Outstanding Number of Options">90,620</td> <td style="background-color: #CCEEFF"> </td> <td style="background-color: #CCEEFF"> </td> <td style="background-color: #CCEEFF"> </td> <td style="background-color: #CCEEFF; text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range03Member__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zUuOZbBs2Lye" title="Weighted Average Remaining Life In Years">3.24</td> <td style="background-color: #CCEEFF"> </td> <td style="background-color: #CCEEFF"> </td> <td style="background-color: #CCEEFF"> </td> <td style="background-color: #CCEEFF; text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range03Member__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Excercisable Number of Options">30,207</td> <td style="background-color: #CCEEFF"> </td> </tr> <tr style="vertical-align: bottom"> <td> </td> <td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range04Member__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Exercise Price">2.95</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range04Member__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Outstanding Number of Options">185,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range04Member__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zJSjAtyf5ljf" title="Weighted Average Remaining Life In Years">3.50</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range04Member__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Excercisable Number of Options">155,000</td> <td> </td> </tr> <tr style="vertical-align: bottom"> <td style="background-color: #CCEEFF"> </td> <td style="background-color: #CCEEFF; text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range05Member__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Exercise Price">3.25</td> <td style="background-color: #CCEEFF"> </td> <td style="background-color: #CCEEFF"> </td> <td style="background-color: #CCEEFF"> </td> <td style="background-color: #CCEEFF; text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range05Member__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Outstanding Number of Options">130,000</td> <td style="background-color: #CCEEFF"> </td> <td style="background-color: #CCEEFF"> </td> <td style="background-color: #CCEEFF"> </td> <td style="background-color: #CCEEFF; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range05Member__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zdXnYo8mA9e1" title="Weighted Average Remaining Life In Years">2.05</td> <td style="background-color: #CCEEFF"> </td> <td style="background-color: #CCEEFF"> </td> <td style="background-color: #CCEEFF"> </td> <td style="background-color: #CCEEFF; text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range05Member__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Excercisable Number of Options">130,000</td> <td style="background-color: #CCEEFF"> </td> </tr> <tr style="vertical-align: bottom"> <td> </td> <td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range06Member__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Exercise Price">1.15</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range06Member__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Outstanding Number of Options">430,435</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range06Member__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zcGQLCqmbhbh" title="Weighted Average Remaining Life In Years">4.06</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range06Member__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Excercisable Number of Options">245,218</td> <td> </td> </tr> <tr style="vertical-align: bottom"> <td style="background-color: #CCEEFF"> </td> <td style="background-color: #CCEEFF; text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range07Member__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Exercise Price">0.96</td> <td style="background-color: #CCEEFF"> </td> <td style="background-color: #CCEEFF"> </td> <td style="background-color: #CCEEFF"> </td> <td style="background-color: #CCEEFF; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range07Member__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Outstanding Number of Options">315,104</td> <td style="background-color: #CCEEFF"> </td> <td style="background-color: #CCEEFF"> </td> <td style="background-color: #CCEEFF"> </td> <td style="background-color: #CCEEFF; text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range07Member__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zrX0OFWeuax3" title="Weighted Average Remaining Life In Years">4.17</td> <td style="background-color: #CCEEFF"> </td> <td style="background-color: #CCEEFF"> </td> <td style="background-color: #CCEEFF"> </td> <td style="background-color: #CCEEFF; text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range07Member__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Excercisable Number of Options">315,104</td> <td style="background-color: #CCEEFF"> </td> </tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 0.5pt"> </td> <td style="text-align: right; padding-bottom: 0.5pt"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range08Member__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Exercise Price">1.50</td> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range08Member__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Outstanding Number of Options">200,000</td> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range08Member__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zUuYMvALLyda" title="Weighted Average Remaining Life In Years">4.28</td> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range08Member__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Excercisable Number of Options">200,000</td> <td style="padding-bottom: 0.5pt"> </td> </tr> <tr style="vertical-align: bottom"> <td style="background-color: #CCEEFF; padding-bottom: 1.25pt"> </td> <td style="background-color: #CCEEFF; padding-bottom: 1.25pt"> </td> <td style="background-color: #CCEEFF; padding-bottom: 1.25pt"> </td> <td style="background-color: #CCEEFF; padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; background-color: #CCEEFF"> </td> <td style="border-bottom: Black 2.5pt double; background-color: #CCEEFF; text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Outstanding Number of Options">4,113,617</td> <td style="background-color: #CCEEFF; padding-bottom: 1.25pt"> </td> <td style="background-color: #CCEEFF; padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; background-color: #CCEEFF; text-align: justify">$</td> <td style="border-bottom: Black 2.5pt double; background-color: #CCEEFF; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zBycLw1CWnR" title="Weighted Average Remaining Life In Years">5.31</td> <td style="background-color: #CCEEFF; padding-bottom: 1.25pt"> </td> <td style="background-color: #CCEEFF; padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; background-color: #CCEEFF"> </td> <td style="border-bottom: Black 2.5pt double; background-color: #CCEEFF; text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Excercisable Number of Options">3,837,986</td> <td style="background-color: #CCEEFF; padding-bottom: 1.25pt"> </td> </tr> </table>

4113617

1.12

P5Y9M18D

4113617

1.12

P5Y3M21D

<table cellpadding="0" cellspacing="0" id="xdx_897_ecustom--ScheduleOfAdditionalIinformationTableTextBlock_zbmhUgrB5M39" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (Details 1)"> <tr style="vertical-align: bottom"> <td id="xdx_8B3_zQV23P999Y66" style="display: none">Schedule of additional information about stock options</td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Exercise Price</td> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Outstanding Number of Options</td> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Remaining Life In Years</td> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Exercisable Number of Options</td> <td style="padding-bottom: 0.5pt"> </td> </tr> <tr style="vertical-align: bottom"> <td style="background-color: #CCEEFF; text-align: justify; width: 1%">$</td> <td style="background-color: #CCEEFF; text-align: right; width: 23%"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range01Member__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Exercise Price">0.89</td> <td style="background-color: #CCEEFF; width: 1%"> </td> <td style="background-color: #CCEEFF; width: 1%"> </td> <td style="background-color: #CCEEFF; width: 1%"> </td> <td style="background-color: #CCEEFF; text-align: right; width: 22%"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range01Member__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Outstanding Number of Options">2,181,208</td> <td style="background-color: #CCEEFF; width: 1%"> </td> <td style="background-color: #CCEEFF; width: 1%"> </td> <td style="background-color: #CCEEFF; text-align: justify; width: 1%">$</td> <td style="background-color: #CCEEFF; text-align: right; width: 22%"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range01Member__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z2OUh8WwnwVe" title="Weighted Average Remaining Life In Years">7.01</td> <td style="background-color: #CCEEFF; width: 1%"> </td> <td style="background-color: #CCEEFF; width: 1%"> </td> <td style="background-color: #CCEEFF; width: 1%"> </td> <td style="background-color: #CCEEFF; text-align: right; width: 22%"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range01Member__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Excercisable Number of Options">2,181,208</td> <td style="background-color: #CCEEFF; width: 1%"> </td> </tr> <tr style="vertical-align: bottom"> <td> </td> <td style="text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range02Member__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Exercise Price">0.94</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range02Member__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Outstanding Number of Options">581,250</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range02Member__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zAtY3dtX2RDe" title="Weighted Average Remaining Life In Years">2.45</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range02Member__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Excercisable Number of Options">581,250</td> <td> </td> </tr> <tr style="vertical-align: bottom"> <td style="background-color: #CCEEFF"> </td> <td style="background-color: #CCEEFF; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range03Member__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Exercise Price">0.66</td> <td style="background-color: #CCEEFF"> </td> <td style="background-color: #CCEEFF"> </td> <td style="background-color: #CCEEFF"> </td> <td style="background-color: #CCEEFF; text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range03Member__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Outstanding Number of Options">90,620</td> <td style="background-color: #CCEEFF"> </td> <td style="background-color: #CCEEFF"> </td> <td style="background-color: #CCEEFF"> </td> <td style="background-color: #CCEEFF; text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range03Member__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zUuOZbBs2Lye" title="Weighted Average Remaining Life In Years">3.24</td> <td style="background-color: #CCEEFF"> </td> <td style="background-color: #CCEEFF"> </td> <td style="background-color: #CCEEFF"> </td> <td style="background-color: #CCEEFF; text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range03Member__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Excercisable Number of Options">30,207</td> <td style="background-color: #CCEEFF"> </td> </tr> <tr style="vertical-align: bottom"> <td> </td> <td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range04Member__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Exercise Price">2.95</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range04Member__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Outstanding Number of Options">185,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range04Member__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zJSjAtyf5ljf" title="Weighted Average Remaining Life In Years">3.50</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range04Member__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Excercisable Number of Options">155,000</td> <td> </td> </tr> <tr style="vertical-align: bottom"> <td style="background-color: #CCEEFF"> </td> <td style="background-color: #CCEEFF; text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range05Member__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Exercise Price">3.25</td> <td style="background-color: #CCEEFF"> </td> <td style="background-color: #CCEEFF"> </td> <td style="background-color: #CCEEFF"> </td> <td style="background-color: #CCEEFF; text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range05Member__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Outstanding Number of Options">130,000</td> <td style="background-color: #CCEEFF"> </td> <td style="background-color: #CCEEFF"> </td> <td style="background-color: #CCEEFF"> </td> <td style="background-color: #CCEEFF; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range05Member__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zdXnYo8mA9e1" title="Weighted Average Remaining Life In Years">2.05</td> <td style="background-color: #CCEEFF"> </td> <td style="background-color: #CCEEFF"> </td> <td style="background-color: #CCEEFF"> </td> <td style="background-color: #CCEEFF; text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range05Member__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Excercisable Number of Options">130,000</td> <td style="background-color: #CCEEFF"> </td> </tr> <tr style="vertical-align: bottom"> <td> </td> <td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range06Member__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Exercise Price">1.15</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range06Member__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Outstanding Number of Options">430,435</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range06Member__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zcGQLCqmbhbh" title="Weighted Average Remaining Life In Years">4.06</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range06Member__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Excercisable Number of Options">245,218</td> <td> </td> </tr> <tr style="vertical-align: bottom"> <td style="background-color: #CCEEFF"> </td> <td style="background-color: #CCEEFF; text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range07Member__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Exercise Price">0.96</td> <td style="background-color: #CCEEFF"> </td> <td style="background-color: #CCEEFF"> </td> <td style="background-color: #CCEEFF"> </td> <td style="background-color: #CCEEFF; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range07Member__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Outstanding Number of Options">315,104</td> <td style="background-color: #CCEEFF"> </td> <td style="background-color: #CCEEFF"> </td> <td style="background-color: #CCEEFF"> </td> <td style="background-color: #CCEEFF; text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range07Member__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zrX0OFWeuax3" title="Weighted Average Remaining Life In Years">4.17</td> <td style="background-color: #CCEEFF"> </td> <td style="background-color: #CCEEFF"> </td> <td style="background-color: #CCEEFF"> </td> <td style="background-color: #CCEEFF; text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range07Member__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Excercisable Number of Options">315,104</td> <td style="background-color: #CCEEFF"> </td> </tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 0.5pt"> </td> <td style="text-align: right; padding-bottom: 0.5pt"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range08Member__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Exercise Price">1.50</td> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range08Member__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Outstanding Number of Options">200,000</td> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range08Member__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zUuYMvALLyda" title="Weighted Average Remaining Life In Years">4.28</td> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Range08Member__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Excercisable Number of Options">200,000</td> <td style="padding-bottom: 0.5pt"> </td> </tr> <tr style="vertical-align: bottom"> <td style="background-color: #CCEEFF; padding-bottom: 1.25pt"> </td> <td style="background-color: #CCEEFF; padding-bottom: 1.25pt"> </td> <td style="background-color: #CCEEFF; padding-bottom: 1.25pt"> </td> <td style="background-color: #CCEEFF; padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; background-color: #CCEEFF"> </td> <td style="border-bottom: Black 2.5pt double; background-color: #CCEEFF; text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Outstanding Number of Options">4,113,617</td> <td style="background-color: #CCEEFF; padding-bottom: 1.25pt"> </td> <td style="background-color: #CCEEFF; padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; background-color: #CCEEFF; text-align: justify">$</td> <td style="border-bottom: Black 2.5pt double; background-color: #CCEEFF; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zBycLw1CWnR" title="Weighted Average Remaining Life In Years">5.31</td> <td style="background-color: #CCEEFF; padding-bottom: 1.25pt"> </td> <td style="background-color: #CCEEFF; padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; background-color: #CCEEFF"> </td> <td style="border-bottom: Black 2.5pt double; background-color: #CCEEFF; text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Excercisable Number of Options">3,837,986</td> <td style="background-color: #CCEEFF; padding-bottom: 1.25pt"> </td> </tr> </table>

0.89

2181208

P7Y3D

2181208

0.94

581250

P2Y5M12D

581250

0.66

90620

P3Y2M26D

30207

2.95

185000

P3Y6M

155000

3.25

130000

P2Y18D

130000

1.15

430435

P4Y21D

245218

0.96

315104

P4Y2M1D

315104

1.50

200000

P4Y3M10D

200000

4113617

P5Y3M21D

3837986

NOTE 9 — COMMITMENT AND CONTINGENCIES From time to time, the Company may be subject to legal proceedings and claims arising in the ordinary course of business. As of June 30, 2026, the Company was not a party to any material legal proceedings. The Company had no material loss contingencies requiring accrual or disclosure other than the commitments described below. Insomnia FDA Study: On April 17, 2026, the Company entered into a Scope of Work (“SOW”) with Lindus Health Limited (“Lindus Health”), pursuant to a previously executed Master Services Agreement (“MSA”), to provide clinical research organization services for the Company’s pivotal clinical trial of its HALO Clarity device (the “Pivotal Study”). Under the SOW, the Company is obligated to make payments to Lindus Health upon the achievement of specified project milestones and for reimbursable pass-through expenses incurred in connection with the Pivotal Study. Direct fees under the SOW total approximately $945,000, exclusive of certain pass-through expenses. During the three and six months ended June 30, 2026 the company incurred approximately $353,000 and $374,000, respectively, under this SOW, including certain pass-through expenses. The term of the SOW continues until completion of all services described therein, unless terminated earlier in accordance with the MSA. The SOW provides that certain changes to the Pivotal Study, such as addition of new clinical sites, increases in enrolled participants, protocol amendments after study start-up, amendments to critical analyses, extension of study duration, and requests for additional platform features or integrations, will require a change order, which may result in adjustments to the scope, budget, or timeline. Subsequent to June 30, 2026, and prior to the issuance of these unaudited condensed consolidated financial statements, the Company entered into a novation agreement pursuant to which Curavit Clinical Research, Inc. assumed Lindus Health’s rights and obligations under the MSA and SOW. The novation did not materially modify the Company’s rights or obligations under the agreements.

945000 353000 374000

NOTE 10 — SEGMENT INFORMATION The Company operates as a single reportable segment, consisting of the design and development of innovative neurostimulation products. The Company’s focus is on treating mental health conditions without reliance on drugs or psychotherapy. Consistent with its operational structure, the Chief Executive Officer, who serves as the chief operating decision maker (“CODM”), manages and allocates resources on a consolidated basis. Financial performance is evaluated based on consolidated net loss, which is also the primary measure used to allocate resources, assess operational performance, set targets, forecast results, and guide strategic decisions, including investments in research and development and commercialization activities. The CODM monitors segment performance using consolidated net loss and total consolidated assets, which are reported on the unaudited condensed consolidated statements of operations and balance sheets, respectively. Consolidated net loss is compared against budgeted amounts on a quarterly basis to evaluate performance. The following table summarizes financial information for the Company’s single reportable segment and reconciles to unaudited condensed consolidated net loss: <table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_z7vZcou2bE39" style="font: 10pt Times New Roman; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SEGMENT INFORMATION (Details)"> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td id="xdx_8B1_zX4nfZLF8N6l" style="display: none; padding-left: 0.25in; text-indent: -0.125in; text-align: left; vertical-align: top">Schedule of segment reporting information</td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_494_20260401__20260630_z4o01KhlYS84" style="text-align: right"> </td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_495_20250401__20250630_zYKr2Cute933" style="text-align: right"> </td> <td style="white-space: nowrap; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <th style="text-align: left; padding-bottom: 0.5pt"> </th> <th style="text-align: center; padding-bottom: 0.5pt"> </th> <th colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Three Months Ended June 30,</th> <th style="text-align: center; padding-bottom: 0.5pt"> </th> </tr> <tr style="vertical-align: bottom"> <th style="text-align: left; padding-bottom: 0.5pt"> </th> <th style="text-align: center; padding-bottom: 0.5pt"> </th> <th colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</th> <th style="text-align: center; padding-bottom: 0.5pt"> </th> <th style="text-align: center; padding-bottom: 0.5pt"> </th> <th colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</th> <th style="text-align: center; padding-bottom: 0.5pt"> </th> </tr> <tr id="xdx_40D_eus-gaap--RevenuesAbstract_iB_zo7bQ2UrEv3c" style="background-color: #CCEEFF; vertical-align: bottom"> <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top">Total revenues</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 9%; text-align: right"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 9%; text-align: right"> </td> <td style="width: 1%; text-align: left"> </td> </tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; vertical-align: top">US</td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">12,161</td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">11,112</td> <td style="white-space: nowrap; text-align: left"> </td> </tr> <tr style="background-color: #CCEEFF; vertical-align: bottom"> <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; vertical-align: top; padding-bottom: 0.5pt">International</td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">-</td> <td style="white-space: nowrap; text-align: left; padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">59,476</td> <td style="white-space: nowrap; text-align: left; padding-bottom: 0.5pt"> </td> </tr> <tr id="xdx_40D_eus-gaap--Revenues_zAHXXDMYyfWg" style="background-color: #FFFFFF; vertical-align: bottom"> <td style="padding-left: 0.375in; text-indent: -0.125in; text-align: left; vertical-align: top">Total revenues</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">12,161</td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">70,588</td> <td style="white-space: nowrap; text-align: left"> </td> </tr> <tr style="background-color: #CCEEFF; vertical-align: bottom"> <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top">Less:</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap; text-align: left"> </td> </tr> <tr id="xdx_408_eus-gaap--CostOfRevenue_i_pp0p" style="background-color: #FFFFFF; vertical-align: bottom"> <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; vertical-align: top">Cost of revenues (excluding amortization and depreciation)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">3,264</td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">22,838</td> <td style="white-space: nowrap; text-align: left"> </td> </tr> <tr id="xdx_40F_eus-gaap--ResearchAndDevelopmentExpenseAbstract_iB_z40FgOuBtxYj" style="background-color: #CCEEFF; vertical-align: bottom"> <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; vertical-align: top">Research and development expense (excluding stock based compensation expense):</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap; text-align: left"> </td> </tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="padding-left: 0.375in; text-indent: -0.125in; text-align: left; vertical-align: top">Clinical trials</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">457,975</td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">60,226</td> <td style="white-space: nowrap; text-align: left"> </td> </tr> <tr style="background-color: #CCEEFF; vertical-align: bottom"> <td style="padding-left: 0.375in; text-indent: -0.125in; text-align: left; vertical-align: top">EDC Build</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">53,795</td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">61,950</td> <td style="white-space: nowrap; text-align: left"> </td> </tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="padding-left: 0.375in; text-indent: -0.125in; text-align: left; vertical-align: top">Halo project</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">20,780</td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">90,534</td> <td style="white-space: nowrap; text-align: left"> </td> </tr> <tr style="background-color: #CCEEFF; vertical-align: bottom"> <td style="padding-left: 0.375in; text-indent: -0.125in; text-align: left; vertical-align: top">SYNC project</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">16,451</td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">11,700</td> <td style="white-space: nowrap; text-align: left"> </td> </tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="padding-left: 0.375in; text-indent: -0.125in; text-align: left; vertical-align: top">Other research and development</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_90E_eus-gaap--ResearchAndDevelopmentExpense_pp0d_c20260401__20260630__us-gaap--StatementBusinessSegmentsAxis__custom--OtherResearchAndDevelopmentMember_ztJO0guFxCG" title="Other research and development">15,479</td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_905_eus-gaap--ResearchAndDevelopmentExpense_pp0d_c20250401__20250630__us-gaap--StatementBusinessSegmentsAxis__custom--OtherResearchAndDevelopmentMember_zLMeAuDetsG2" title="Other research and development">1,364</td> <td style="white-space: nowrap; text-align: left"> </td> </tr> <tr id="xdx_40B_eus-gaap--GeneralAndAdministrativeExpense_i_pp0p" style="background-color: #CCEEFF; vertical-align: bottom"> <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; vertical-align: top">Selling, general and administrative and Salaries and benefits expense (excluding stock based compensation, depreciation and amortization expense)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">852,838</td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">687,011</td> <td style="white-space: nowrap; text-align: left"> </td> </tr> <tr id="xdx_404_eus-gaap--DepreciationAndAmortization_i_pp0p" style="background-color: #FFFFFF; vertical-align: bottom"> <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; vertical-align: top">Depreciation</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">2,738</td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">-</td> <td style="white-space: nowrap; text-align: left"> </td> </tr> <tr id="xdx_40A_eus-gaap--AdjustmentForAmortization_i_pp0p" style="background-color: #CCEEFF; vertical-align: bottom"> <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; vertical-align: top">Amortization</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">20,325</td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">5,126</td> <td style="white-space: nowrap; text-align: left"> </td> </tr> <tr id="xdx_40E_eus-gaap--EmployeeBenefitsAndShareBasedCompensationNoncash_i_pp0p" style="background-color: #FFFFFF; vertical-align: bottom"> <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; vertical-align: top">Stock based compensation</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">408,387</td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">572,100</td> <td style="white-space: nowrap; text-align: left"> </td> </tr> <tr id="xdx_404_eus-gaap--ProfessionalFees_i_pp0p" style="background-color: #CCEEFF; vertical-align: bottom"> <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; vertical-align: top">Professional fees</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">407,444</td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">178,597</td> <td style="white-space: nowrap; text-align: left"> </td> </tr> <tr id="xdx_40D_eus-gaap--InterestIncomeExpenseNet_i_pp0p" style="background-color: #FFFFFF; vertical-align: bottom"> <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; vertical-align: top">Interest income, net</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(129</td> <td style="white-space: nowrap; text-align: left">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(4,690</td> <td style="white-space: nowrap; text-align: left">)</td> </tr> <tr id="xdx_409_eus-gaap--OtherNonoperatingIncome_iN_pp0d_di_zRI4CiiwnOWh" style="background-color: #CCEEFF; vertical-align: bottom"> <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; vertical-align: top; padding-bottom: 0.5pt">Other income</td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">(8,016</td> <td style="white-space: nowrap; text-align: left; padding-bottom: 0.5pt">)</td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">(35,181</td> <td style="white-space: nowrap; text-align: left; padding-bottom: 0.5pt">)</td> </tr> <tr id="xdx_40F_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zon9JwI3EzA1" style="background-color: #FFFFFF; vertical-align: bottom"> <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top; padding-bottom: 0.5pt">Segment net loss</td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">(2,239,170</td> <td style="white-space: nowrap; text-align: left; padding-bottom: 0.5pt">)</td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">(1,580,987</td> <td style="white-space: nowrap; text-align: left; padding-bottom: 0.5pt">)</td> </tr> <tr style="background-color: #CCEEFF; vertical-align: bottom"> <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap; text-align: left"> </td> </tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top">Reconciliation of net loss</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap; text-align: left"> </td> </tr> <tr id="xdx_40E_ecustom--AdjustmentsAndReconcilingItems_i_pp0p" style="background-color: #CCEEFF; vertical-align: bottom"> <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top; padding-bottom: 0.5pt">Adjustments and reconciling items</td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">-</td> <td style="white-space: nowrap; text-align: left; padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">-</td> <td style="white-space: nowrap; text-align: left; padding-bottom: 0.5pt"> </td> </tr> <tr id="xdx_406_eus-gaap--NetIncomeLoss_ztfUxtE1I7xl" style="background-color: #FFFFFF; vertical-align: bottom"> <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top; padding-bottom: 1.25pt">Consolidated net loss</td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">(2,239,170</td> <td style="white-space: nowrap; text-align: left; padding-bottom: 1.25pt">)</td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">(1,580,987</td> <td style="white-space: nowrap; text-align: left; padding-bottom: 1.25pt">)</td> </tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman; border-collapse: collapse; width: 100%"> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; vertical-align: top"> </td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_493_20260101__20260630_zvI0mrvNBMUh" style="text-align: right"> </td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_49E_20250101__20250630_zWeOseUAyLsg" style="text-align: right"> </td> <td style="white-space: nowrap; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <th style="text-align: left; padding-bottom: 0.5pt"> </th> <th style="text-align: center; padding-bottom: 0.5pt"> </th> <th colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Six Months Ended June 30,</th> <th style="text-align: center; padding-bottom: 0.5pt"> </th> </tr> <tr style="vertical-align: bottom"> <th style="text-align: left; padding-bottom: 0.5pt"> </th> <th style="text-align: center; padding-bottom: 0.5pt"> </th> <th colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</th> <th style="text-align: center; padding-bottom: 0.5pt"> </th> <th style="text-align: center; padding-bottom: 0.5pt"> </th> <th colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</th> <th style="text-align: center; padding-bottom: 0.5pt"> </th> </tr> <tr id="xdx_40F_eus-gaap--RevenuesAbstract_iB_zlG35vStdv3k" style="background-color: #CCEEFF; vertical-align: bottom"> <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top">Total revenues</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 9%; text-align: right"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 9%; text-align: right"> </td> <td style="width: 1%; text-align: left"> </td> </tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; vertical-align: top">US</td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">27,111</td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">31,555</td> <td style="white-space: nowrap; text-align: left"> </td> </tr> <tr style="background-color: #CCEEFF; vertical-align: bottom"> <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; vertical-align: top; padding-bottom: 0.5pt">International</td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">-</td> <td style="white-space: nowrap; text-align: left; padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">80,048</td> <td style="white-space: nowrap; text-align: left; padding-bottom: 0.5pt"> </td> </tr> <tr id="xdx_40C_eus-gaap--Revenues_z2Vxlqe22Vik" style="background-color: #FFFFFF; vertical-align: bottom"> <td style="padding-left: 0.375in; text-indent: -0.125in; text-align: left; vertical-align: top">Total revenues</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">27,111</td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">111,603</td> <td style="white-space: nowrap; text-align: left"> </td> </tr> <tr style="background-color: #CCEEFF; vertical-align: bottom"> <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top">Less:</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap; text-align: left"> </td> </tr> <tr id="xdx_406_eus-gaap--CostOfRevenue_zu85NcLeKmGb" style="background-color: #FFFFFF; vertical-align: bottom"> <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; vertical-align: top">Cost of revenues (excluding amortization and depreciation)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">5,081</td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">36,396</td> <td style="white-space: nowrap; text-align: left"> </td> </tr> <tr id="xdx_40F_eus-gaap--ResearchAndDevelopmentExpenseAbstract_iB_zfn4swkyi5Wc" style="background-color: #CCEEFF; vertical-align: bottom"> <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; vertical-align: top">Research and development expense (excluding stock based compensation expense):</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap; text-align: left"> </td> </tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="padding-left: 0.375in; text-indent: -0.125in; text-align: left; vertical-align: top">Clinical trials</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">656,421</td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">121,578</td> <td style="white-space: nowrap; text-align: left"> </td> </tr> <tr style="background-color: #CCEEFF; vertical-align: bottom"> <td style="padding-left: 0.375in; text-indent: -0.125in; text-align: left; vertical-align: top">EDC Build</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">109,595</td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">80,000</td> <td style="white-space: nowrap; text-align: left"> </td> </tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="padding-left: 0.375in; text-indent: -0.125in; text-align: left; vertical-align: top">Halo project</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">109,547</td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">388,571</td> <td style="white-space: nowrap; text-align: left"> </td> </tr> <tr style="background-color: #CCEEFF; vertical-align: bottom"> <td style="padding-left: 0.375in; text-indent: -0.125in; text-align: left; vertical-align: top">SYNC project</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">16,451</td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">35,413</td> <td style="white-space: nowrap; text-align: left"> </td> </tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="padding-left: 0.375in; text-indent: -0.125in; text-align: left; vertical-align: top">Other research and development</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_90F_eus-gaap--ResearchAndDevelopmentExpense_pp0d_c20260101__20260630__us-gaap--StatementBusinessSegmentsAxis__custom--OtherResearchAndDevelopmentMember_zpDmPKiAAQlg" title="Other research and development">18,848</td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_901_eus-gaap--ResearchAndDevelopmentExpense_pp0d_c20250101__20250630__us-gaap--StatementBusinessSegmentsAxis__custom--OtherResearchAndDevelopmentMember_zJ0d0Ozmor82" title="Other research and development">6,500</td> <td style="white-space: nowrap; text-align: left"> </td> </tr> <tr id="xdx_40E_eus-gaap--GeneralAndAdministrativeExpense_za9NMZa0z8E8" style="background-color: #CCEEFF; vertical-align: bottom"> <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; vertical-align: top">Selling, general and administrative and Salaries and benefits expense (excluding stock based compensation, depreciation and amortization expense)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">1,654,742</td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">1,309,959</td> <td style="white-space: nowrap; text-align: left"> </td> </tr> <tr id="xdx_40D_eus-gaap--DepreciationAndAmortization_zob3nGOjI374" style="background-color: #FFFFFF; vertical-align: bottom"> <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; vertical-align: top">Depreciation</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">6,844</td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">-</td> <td style="white-space: nowrap; text-align: left"> </td> </tr> <tr id="xdx_400_eus-gaap--AdjustmentForAmortization_zuJqa5Pk86b2" style="background-color: #CCEEFF; vertical-align: bottom"> <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; vertical-align: top">Amortization</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">27,061</td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">9,912</td> <td style="white-space: nowrap; text-align: left"> </td> </tr> <tr id="xdx_40A_eus-gaap--EmployeeBenefitsAndShareBasedCompensationNoncash_zGOECjuDy9I8" style="background-color: #FFFFFF; vertical-align: bottom"> <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; vertical-align: top">Stock based compensation</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">886,998</td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">1,208,944</td> <td style="white-space: nowrap; text-align: left"> </td> </tr> <tr id="xdx_401_eus-gaap--ProfessionalFees_zhn0WjGuUEq6" style="background-color: #CCEEFF; vertical-align: bottom"> <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; vertical-align: top">Professional fees</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">902,740</td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">546,413</td> <td style="white-space: nowrap; text-align: left"> </td> </tr> <tr id="xdx_408_eus-gaap--InterestIncomeExpenseNet_zVvyEQ12YXg3" style="background-color: #FFFFFF; vertical-align: bottom"> <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; vertical-align: top">Interest income, net</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(163</td> <td style="white-space: nowrap; text-align: left">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(5,793</td> <td style="white-space: nowrap; text-align: left">)</td> </tr> <tr id="xdx_409_ecustom--EquityInNetIncomeFromEquityMethodInvestees_iP3us-gaap--InterestIncomeExpenseNet_zJKltJ9xSKY9" style="background-color: #CCEEFF; vertical-align: bottom"> <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; vertical-align: top">Equity in net income from equity method investees</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">-</td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">1,048</td> <td style="white-space: nowrap; text-align: left"> </td> </tr> <tr id="xdx_401_eus-gaap--OtherNonoperatingIncome_iN_pp0d_di_zEzrsemKLXIe" style="background-color: #FFFFFF; vertical-align: bottom"> <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; vertical-align: top; padding-bottom: 0.5pt">Other income</td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">(31,047</td> <td style="white-space: nowrap; text-align: left; padding-bottom: 0.5pt">)</td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">(58,014</td> <td style="white-space: nowrap; text-align: left; padding-bottom: 0.5pt">)</td> </tr> <tr id="xdx_40C_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zPb7HwpbpYgc" style="background-color: #CCEEFF; vertical-align: bottom"> <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top; padding-bottom: 0.5pt">Segment net loss</td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">(4,336,007</td> <td style="white-space: nowrap; text-align: left; padding-bottom: 0.5pt">)</td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">(3,569,324</td> <td style="white-space: nowrap; text-align: left; padding-bottom: 0.5pt">)</td> </tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap; text-align: left"> </td> </tr> <tr style="background-color: #CCEEFF; vertical-align: bottom"> <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top">Reconciliation of net loss</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap; text-align: left"> </td> </tr> <tr id="xdx_405_ecustom--AdjustmentsAndReconcilingItems_zdpsWUsleVz2" style="background-color: #FFFFFF; vertical-align: bottom"> <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top; padding-bottom: 0.5pt">Adjustments and reconciling items</td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">-</td> <td style="white-space: nowrap; text-align: left; padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">-</td> <td style="white-space: nowrap; text-align: left; padding-bottom: 0.5pt"> </td> </tr> <tr id="xdx_408_eus-gaap--NetIncomeLoss_z51S3IAf9qo" style="background-color: #CCEEFF; vertical-align: bottom"> <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top; padding-bottom: 1.25pt">Consolidated net loss</td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">(4,336,007</td> <td style="white-space: nowrap; text-align: left; padding-bottom: 1.25pt">)</td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">(3,569,324</td> <td style="white-space: nowrap; text-align: left; padding-bottom: 1.25pt">)</td> </tr> </table>

<table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_z7vZcou2bE39" style="font: 10pt Times New Roman; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SEGMENT INFORMATION (Details)"> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td id="xdx_8B1_zX4nfZLF8N6l" style="display: none; padding-left: 0.25in; text-indent: -0.125in; text-align: left; vertical-align: top">Schedule of segment reporting information</td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_494_20260401__20260630_z4o01KhlYS84" style="text-align: right"> </td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_495_20250401__20250630_zYKr2Cute933" style="text-align: right"> </td> <td style="white-space: nowrap; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <th style="text-align: left; padding-bottom: 0.5pt"> </th> <th style="text-align: center; padding-bottom: 0.5pt"> </th> <th colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Three Months Ended June 30,</th> <th style="text-align: center; padding-bottom: 0.5pt"> </th> </tr> <tr style="vertical-align: bottom"> <th style="text-align: left; padding-bottom: 0.5pt"> </th> <th style="text-align: center; padding-bottom: 0.5pt"> </th> <th colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</th> <th style="text-align: center; padding-bottom: 0.5pt"> </th> <th style="text-align: center; padding-bottom: 0.5pt"> </th> <th colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</th> <th style="text-align: center; padding-bottom: 0.5pt"> </th> </tr> <tr id="xdx_40D_eus-gaap--RevenuesAbstract_iB_zo7bQ2UrEv3c" style="background-color: #CCEEFF; vertical-align: bottom"> <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top">Total revenues</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 9%; text-align: right"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 9%; text-align: right"> </td> <td style="width: 1%; text-align: left"> </td> </tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; vertical-align: top">US</td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">12,161</td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">11,112</td> <td style="white-space: nowrap; text-align: left"> </td> </tr> <tr style="background-color: #CCEEFF; vertical-align: bottom"> <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; vertical-align: top; padding-bottom: 0.5pt">International</td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">-</td> <td style="white-space: nowrap; text-align: left; padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">59,476</td> <td style="white-space: nowrap; text-align: left; padding-bottom: 0.5pt"> </td> </tr> <tr id="xdx_40D_eus-gaap--Revenues_zAHXXDMYyfWg" style="background-color: #FFFFFF; vertical-align: bottom"> <td style="padding-left: 0.375in; text-indent: -0.125in; text-align: left; vertical-align: top">Total revenues</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">12,161</td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">70,588</td> <td style="white-space: nowrap; text-align: left"> </td> </tr> <tr style="background-color: #CCEEFF; vertical-align: bottom"> <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top">Less:</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap; text-align: left"> </td> </tr> <tr id="xdx_408_eus-gaap--CostOfRevenue_i_pp0p" style="background-color: #FFFFFF; vertical-align: bottom"> <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; vertical-align: top">Cost of revenues (excluding amortization and depreciation)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">3,264</td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">22,838</td> <td style="white-space: nowrap; text-align: left"> </td> </tr> <tr id="xdx_40F_eus-gaap--ResearchAndDevelopmentExpenseAbstract_iB_z40FgOuBtxYj" style="background-color: #CCEEFF; vertical-align: bottom"> <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; vertical-align: top">Research and development expense (excluding stock based compensation expense):</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap; text-align: left"> </td> </tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="padding-left: 0.375in; text-indent: -0.125in; text-align: left; vertical-align: top">Clinical trials</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">457,975</td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">60,226</td> <td style="white-space: nowrap; text-align: left"> </td> </tr> <tr style="background-color: #CCEEFF; vertical-align: bottom"> <td style="padding-left: 0.375in; text-indent: -0.125in; text-align: left; vertical-align: top">EDC Build</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">53,795</td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">61,950</td> <td style="white-space: nowrap; text-align: left"> </td> </tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="padding-left: 0.375in; text-indent: -0.125in; text-align: left; vertical-align: top">Halo project</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">20,780</td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">90,534</td> <td style="white-space: nowrap; text-align: left"> </td> </tr> <tr style="background-color: #CCEEFF; vertical-align: bottom"> <td style="padding-left: 0.375in; text-indent: -0.125in; text-align: left; vertical-align: top">SYNC project</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">16,451</td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">11,700</td> <td style="white-space: nowrap; text-align: left"> </td> </tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="padding-left: 0.375in; text-indent: -0.125in; text-align: left; vertical-align: top">Other research and development</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_90E_eus-gaap--ResearchAndDevelopmentExpense_pp0d_c20260401__20260630__us-gaap--StatementBusinessSegmentsAxis__custom--OtherResearchAndDevelopmentMember_ztJO0guFxCG" title="Other research and development">15,479</td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_905_eus-gaap--ResearchAndDevelopmentExpense_pp0d_c20250401__20250630__us-gaap--StatementBusinessSegmentsAxis__custom--OtherResearchAndDevelopmentMember_zLMeAuDetsG2" title="Other research and development">1,364</td> <td style="white-space: nowrap; text-align: left"> </td> </tr> <tr id="xdx_40B_eus-gaap--GeneralAndAdministrativeExpense_i_pp0p" style="background-color: #CCEEFF; vertical-align: bottom"> <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; vertical-align: top">Selling, general and administrative and Salaries and benefits expense (excluding stock based compensation, depreciation and amortization expense)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">852,838</td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">687,011</td> <td style="white-space: nowrap; text-align: left"> </td> </tr> <tr id="xdx_404_eus-gaap--DepreciationAndAmortization_i_pp0p" style="background-color: #FFFFFF; vertical-align: bottom"> <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; vertical-align: top">Depreciation</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">2,738</td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">-</td> <td style="white-space: nowrap; text-align: left"> </td> </tr> <tr id="xdx_40A_eus-gaap--AdjustmentForAmortization_i_pp0p" style="background-color: #CCEEFF; vertical-align: bottom"> <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; vertical-align: top">Amortization</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">20,325</td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">5,126</td> <td style="white-space: nowrap; text-align: left"> </td> </tr> <tr id="xdx_40E_eus-gaap--EmployeeBenefitsAndShareBasedCompensationNoncash_i_pp0p" style="background-color: #FFFFFF; vertical-align: bottom"> <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; vertical-align: top">Stock based compensation</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">408,387</td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">572,100</td> <td style="white-space: nowrap; text-align: left"> </td> </tr> <tr id="xdx_404_eus-gaap--ProfessionalFees_i_pp0p" style="background-color: #CCEEFF; vertical-align: bottom"> <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; vertical-align: top">Professional fees</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">407,444</td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">178,597</td> <td style="white-space: nowrap; text-align: left"> </td> </tr> <tr id="xdx_40D_eus-gaap--InterestIncomeExpenseNet_i_pp0p" style="background-color: #FFFFFF; vertical-align: bottom"> <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; vertical-align: top">Interest income, net</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(129</td> <td style="white-space: nowrap; text-align: left">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(4,690</td> <td style="white-space: nowrap; text-align: left">)</td> </tr> <tr id="xdx_409_eus-gaap--OtherNonoperatingIncome_iN_pp0d_di_zRI4CiiwnOWh" style="background-color: #CCEEFF; vertical-align: bottom"> <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; vertical-align: top; padding-bottom: 0.5pt">Other income</td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">(8,016</td> <td style="white-space: nowrap; text-align: left; padding-bottom: 0.5pt">)</td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">(35,181</td> <td style="white-space: nowrap; text-align: left; padding-bottom: 0.5pt">)</td> </tr> <tr id="xdx_40F_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zon9JwI3EzA1" style="background-color: #FFFFFF; vertical-align: bottom"> <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top; padding-bottom: 0.5pt">Segment net loss</td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">(2,239,170</td> <td style="white-space: nowrap; text-align: left; padding-bottom: 0.5pt">)</td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">(1,580,987</td> <td style="white-space: nowrap; text-align: left; padding-bottom: 0.5pt">)</td> </tr> <tr style="background-color: #CCEEFF; vertical-align: bottom"> <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap; text-align: left"> </td> </tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top">Reconciliation of net loss</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap; text-align: left"> </td> </tr> <tr id="xdx_40E_ecustom--AdjustmentsAndReconcilingItems_i_pp0p" style="background-color: #CCEEFF; vertical-align: bottom"> <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top; padding-bottom: 0.5pt">Adjustments and reconciling items</td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">-</td> <td style="white-space: nowrap; text-align: left; padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">-</td> <td style="white-space: nowrap; text-align: left; padding-bottom: 0.5pt"> </td> </tr> <tr id="xdx_406_eus-gaap--NetIncomeLoss_ztfUxtE1I7xl" style="background-color: #FFFFFF; vertical-align: bottom"> <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top; padding-bottom: 1.25pt">Consolidated net loss</td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">(2,239,170</td> <td style="white-space: nowrap; text-align: left; padding-bottom: 1.25pt">)</td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">(1,580,987</td> <td style="white-space: nowrap; text-align: left; padding-bottom: 1.25pt">)</td> </tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman; border-collapse: collapse; width: 100%"> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; vertical-align: top"> </td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_493_20260101__20260630_zvI0mrvNBMUh" style="text-align: right"> </td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_49E_20250101__20250630_zWeOseUAyLsg" style="text-align: right"> </td> <td style="white-space: nowrap; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <th style="text-align: left; padding-bottom: 0.5pt"> </th> <th style="text-align: center; padding-bottom: 0.5pt"> </th> <th colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Six Months Ended June 30,</th> <th style="text-align: center; padding-bottom: 0.5pt"> </th> </tr> <tr style="vertical-align: bottom"> <th style="text-align: left; padding-bottom: 0.5pt"> </th> <th style="text-align: center; padding-bottom: 0.5pt"> </th> <th colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</th> <th style="text-align: center; padding-bottom: 0.5pt"> </th> <th style="text-align: center; padding-bottom: 0.5pt"> </th> <th colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</th> <th style="text-align: center; padding-bottom: 0.5pt"> </th> </tr> <tr id="xdx_40F_eus-gaap--RevenuesAbstract_iB_zlG35vStdv3k" style="background-color: #CCEEFF; vertical-align: bottom"> <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top">Total revenues</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 9%; text-align: right"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 9%; text-align: right"> </td> <td style="width: 1%; text-align: left"> </td> </tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; vertical-align: top">US</td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">27,111</td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">31,555</td> <td style="white-space: nowrap; text-align: left"> </td> </tr> <tr style="background-color: #CCEEFF; vertical-align: bottom"> <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; vertical-align: top; padding-bottom: 0.5pt">International</td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">-</td> <td style="white-space: nowrap; text-align: left; padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">80,048</td> <td style="white-space: nowrap; text-align: left; padding-bottom: 0.5pt"> </td> </tr> <tr id="xdx_40C_eus-gaap--Revenues_z2Vxlqe22Vik" style="background-color: #FFFFFF; vertical-align: bottom"> <td style="padding-left: 0.375in; text-indent: -0.125in; text-align: left; vertical-align: top">Total revenues</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">27,111</td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">111,603</td> <td style="white-space: nowrap; text-align: left"> </td> </tr> <tr style="background-color: #CCEEFF; vertical-align: bottom"> <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top">Less:</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap; text-align: left"> </td> </tr> <tr id="xdx_406_eus-gaap--CostOfRevenue_zu85NcLeKmGb" style="background-color: #FFFFFF; vertical-align: bottom"> <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; vertical-align: top">Cost of revenues (excluding amortization and depreciation)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">5,081</td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">36,396</td> <td style="white-space: nowrap; text-align: left"> </td> </tr> <tr id="xdx_40F_eus-gaap--ResearchAndDevelopmentExpenseAbstract_iB_zfn4swkyi5Wc" style="background-color: #CCEEFF; vertical-align: bottom"> <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; vertical-align: top">Research and development expense (excluding stock based compensation expense):</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap; text-align: left"> </td> </tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="padding-left: 0.375in; text-indent: -0.125in; text-align: left; vertical-align: top">Clinical trials</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">656,421</td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">121,578</td> <td style="white-space: nowrap; text-align: left"> </td> </tr> <tr style="background-color: #CCEEFF; vertical-align: bottom"> <td style="padding-left: 0.375in; text-indent: -0.125in; text-align: left; vertical-align: top">EDC Build</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">109,595</td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">80,000</td> <td style="white-space: nowrap; text-align: left"> </td> </tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="padding-left: 0.375in; text-indent: -0.125in; text-align: left; vertical-align: top">Halo project</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">109,547</td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">388,571</td> <td style="white-space: nowrap; text-align: left"> </td> </tr> <tr style="background-color: #CCEEFF; vertical-align: bottom"> <td style="padding-left: 0.375in; text-indent: -0.125in; text-align: left; vertical-align: top">SYNC project</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">16,451</td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">35,413</td> <td style="white-space: nowrap; text-align: left"> </td> </tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="padding-left: 0.375in; text-indent: -0.125in; text-align: left; vertical-align: top">Other research and development</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_90F_eus-gaap--ResearchAndDevelopmentExpense_pp0d_c20260101__20260630__us-gaap--StatementBusinessSegmentsAxis__custom--OtherResearchAndDevelopmentMember_zpDmPKiAAQlg" title="Other research and development">18,848</td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_901_eus-gaap--ResearchAndDevelopmentExpense_pp0d_c20250101__20250630__us-gaap--StatementBusinessSegmentsAxis__custom--OtherResearchAndDevelopmentMember_zJ0d0Ozmor82" title="Other research and development">6,500</td> <td style="white-space: nowrap; text-align: left"> </td> </tr> <tr id="xdx_40E_eus-gaap--GeneralAndAdministrativeExpense_za9NMZa0z8E8" style="background-color: #CCEEFF; vertical-align: bottom"> <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; vertical-align: top">Selling, general and administrative and Salaries and benefits expense (excluding stock based compensation, depreciation and amortization expense)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">1,654,742</td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">1,309,959</td> <td style="white-space: nowrap; text-align: left"> </td> </tr> <tr id="xdx_40D_eus-gaap--DepreciationAndAmortization_zob3nGOjI374" style="background-color: #FFFFFF; vertical-align: bottom"> <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; vertical-align: top">Depreciation</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">6,844</td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">-</td> <td style="white-space: nowrap; text-align: left"> </td> </tr> <tr id="xdx_400_eus-gaap--AdjustmentForAmortization_zuJqa5Pk86b2" style="background-color: #CCEEFF; vertical-align: bottom"> <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; vertical-align: top">Amortization</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">27,061</td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">9,912</td> <td style="white-space: nowrap; text-align: left"> </td> </tr> <tr id="xdx_40A_eus-gaap--EmployeeBenefitsAndShareBasedCompensationNoncash_zGOECjuDy9I8" style="background-color: #FFFFFF; vertical-align: bottom"> <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; vertical-align: top">Stock based compensation</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">886,998</td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">1,208,944</td> <td style="white-space: nowrap; text-align: left"> </td> </tr> <tr id="xdx_401_eus-gaap--ProfessionalFees_zhn0WjGuUEq6" style="background-color: #CCEEFF; vertical-align: bottom"> <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; vertical-align: top">Professional fees</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">902,740</td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">546,413</td> <td style="white-space: nowrap; text-align: left"> </td> </tr> <tr id="xdx_408_eus-gaap--InterestIncomeExpenseNet_zVvyEQ12YXg3" style="background-color: #FFFFFF; vertical-align: bottom"> <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; vertical-align: top">Interest income, net</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(163</td> <td style="white-space: nowrap; text-align: left">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(5,793</td> <td style="white-space: nowrap; text-align: left">)</td> </tr> <tr id="xdx_409_ecustom--EquityInNetIncomeFromEquityMethodInvestees_iP3us-gaap--InterestIncomeExpenseNet_zJKltJ9xSKY9" style="background-color: #CCEEFF; vertical-align: bottom"> <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; vertical-align: top">Equity in net income from equity method investees</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">-</td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">1,048</td> <td style="white-space: nowrap; text-align: left"> </td> </tr> <tr id="xdx_401_eus-gaap--OtherNonoperatingIncome_iN_pp0d_di_zEzrsemKLXIe" style="background-color: #FFFFFF; vertical-align: bottom"> <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; vertical-align: top; padding-bottom: 0.5pt">Other income</td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">(31,047</td> <td style="white-space: nowrap; text-align: left; padding-bottom: 0.5pt">)</td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">(58,014</td> <td style="white-space: nowrap; text-align: left; padding-bottom: 0.5pt">)</td> </tr> <tr id="xdx_40C_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zPb7HwpbpYgc" style="background-color: #CCEEFF; vertical-align: bottom"> <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top; padding-bottom: 0.5pt">Segment net loss</td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">(4,336,007</td> <td style="white-space: nowrap; text-align: left; padding-bottom: 0.5pt">)</td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">(3,569,324</td> <td style="white-space: nowrap; text-align: left; padding-bottom: 0.5pt">)</td> </tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap; text-align: left"> </td> </tr> <tr style="background-color: #CCEEFF; vertical-align: bottom"> <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top">Reconciliation of net loss</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap; text-align: left"> </td> </tr> <tr id="xdx_405_ecustom--AdjustmentsAndReconcilingItems_zdpsWUsleVz2" style="background-color: #FFFFFF; vertical-align: bottom"> <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top; padding-bottom: 0.5pt">Adjustments and reconciling items</td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">-</td> <td style="white-space: nowrap; text-align: left; padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">-</td> <td style="white-space: nowrap; text-align: left; padding-bottom: 0.5pt"> </td> </tr> <tr id="xdx_408_eus-gaap--NetIncomeLoss_z51S3IAf9qo" style="background-color: #CCEEFF; vertical-align: bottom"> <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top; padding-bottom: 1.25pt">Consolidated net loss</td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">(4,336,007</td> <td style="white-space: nowrap; text-align: left; padding-bottom: 1.25pt">)</td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">(3,569,324</td> <td style="white-space: nowrap; text-align: left; padding-bottom: 1.25pt">)</td> </tr> </table>

12161

11112

59476

12161

70588

3264

22838

457975

60226

53795

61950

20780

90534

16451

11700

15479

1364

852838

687011

2738

20325

5126

408387

572100

407444

178597

-129

-4690

8016

35181

-2239170

-1580987

-2239170

-1580987

27111

31555

80048

27111

111603

5081

36396

656421

121578

109595

80000

109547

388571

16451

35413

18848

6500

1654742

1309959

6844

27061

9912

886998

1208944

902740

546413

-163

-5793

1048

31047

58014

-4336007

-3569324

-4336007

-3569324

NOTE 11 — SUBSEQUENT EVENTS The Company evaluated subsequent events through the date these unaudited condensed consolidated financial statements were issued. Annual Shareholder Meeting On August 11, 2026, the Company held its 2026 Annual Meeting of Stockholders. At the meeting, the <span id="xdx_905_ecustom--AnnualShareholderMeetingDescription_c20260801__20260811__us-gaap--PlanNameAxis__custom--N2023EquityCompensationPlanMember_zoz5kECifuwk" title="Annual shareholder meeting description">Company’s stockholders elected the Company’s nominated directors, ratified the appointment of CBIZ CPAs P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026, approved the termination of the Company’s 2023 Equity Compensation Plan, and approved the Company’s 2026 Equity Compensation Plan, pursuant to which up to 7,000,000 shares of the Company’s common stock may be issued. Awards outstanding under the 2023 Equity Compensation Plan will continue to be governed by the terms of that plan until exercised, settled, forfeited or otherwise terminated in accordance with their terms. The Company’s stockholders also approved an amendment to the Company’s Amended and Restated Certificate of Incorporation authorizing the Board of Directors, in its discretion, to effect one or more reverse stock splits of the Company’s issued and outstanding common stock at a ratio of any whole number between and including 1-for-2 and 1-for-100, provided that the aggregate of all reverse stock splits implemented pursuant to such authority does not exceed 1-for-250, and subject to the Board of Directors’ authority to abandon any such amendment. As of the date these unaudited condensed consolidated financial statements were issued, the Board of Directors has approved a 30 to 1 reverse stock split ratio, but this has not gone into effect as of yet. Office Lease Amendment On July 28, 2026, the Company entered into a Third Amendment to Office Lease (the “Third Amendment”) with Nutex HQ LLC (the “Landlord”), effective as of March 1, 2026, amending the Company’s existing office lease for its corporate headquarters located at 1776 Yorktown, Suite 500, Houston, Texas 77056. The Third Amendment extends the lease term for 65 months and provides for the expansion of the leased premises from approximately 3,623 rentable square feet to approximately 4,527 rentable square feet through the addition of approximately 904 rentable square feet, with the expansion space becoming subject to the lease upon its applicable commencement date. The Company’s initial monthly base rent for the existing premises is approximately $5,000 and, following commencement of the expansion space, monthly base rent for the combined premises will range from approximately $5,000 to $6,000 over the lease term, subject to annual increases. The Third Amendment also provides for a five-month conditional abatement of base rent following commencement of the expansion space, subject to the Company’s compliance with the lease terms, and requires the Company to pay its proportionate share of operating expenses and real property taxes. In addition, the Company has one option to extend the lease for an additional five-year term at the then-prevailing market rental rate. The Company expects to account for the Third Amendment as a lease modification in the third quarter of 2026 in accordance with ASC 842.

Company’s stockholders elected the Company’s nominated directors, ratified the appointment of CBIZ CPAs P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026, approved the termination of the Company’s 2023 Equity Compensation Plan, and approved the Company’s 2026 Equity Compensation Plan, pursuant to which up to 7,000,000 shares of the Company’s common stock may be issued. The Company’s initial monthly base rent for the existing premises is approximately $5,000 and, following commencement of the expansion space, monthly base rent for the combined premises will range from approximately $5,000 to $6,000 over the lease term, subject to annual increases. false false false false